<html>

<head>
<meta http-equiv=Content-Type content="text/html; charset=us-ascii">
<meta name=Generator content="Microsoft Word 15 (filtered)">
<title>ANNEX I</title>
<style>
<!--
 /* Font Definitions */
 @font-face
	{font-family:Wingdings;
	panose-1:5 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:SimSun;
	panose-1:2 1 6 0 3 1 1 1 1 1;}
@font-face
	{font-family:"Cambria Math";
	panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
	{font-family:Verdana;
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:Tahoma;
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:"\@SimSun";
	panose-1:2 1 6 0 3 1 1 1 1 1;}
@font-face
	{font-family:TimesNewRoman;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:HelveticaNeueLTStd-Cn;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:Wingdings-Regular;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@HelveticaNeueLTStd-Cn";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Wingdings-Regular";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
 /* Style Definitions */
 p.MsoNormal, li.MsoNormal, div.MsoNormal
	{margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
h1
	{margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:0in;
	text-indent:0in;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	text-transform:uppercase;}
h2
	{margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:0in;
	text-indent:0in;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
h3
	{margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:0in;
	text-indent:0in;
	page-break-after:avoid;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
h4
	{margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:0in;
	text-indent:0in;
	page-break-after:avoid;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	font-style:italic;}
h5
	{margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:0in;
	text-indent:0in;
	font-size:11.0pt;
	font-family:"Arial",sans-serif;
	font-weight:normal;}
h6
	{margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:0in;
	text-indent:0in;
	font-size:11.0pt;
	font-family:"Arial",sans-serif;
	font-weight:normal;
	font-style:italic;}
p.MsoHeading7, li.MsoHeading7, div.MsoHeading7
	{margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:0in;
	text-indent:0in;
	font-size:11.0pt;
	font-family:"Arial",sans-serif;}
p.MsoHeading8, li.MsoHeading8, div.MsoHeading8
	{margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:0in;
	text-indent:0in;
	font-size:11.0pt;
	font-family:"Arial",sans-serif;
	font-style:italic;}
p.MsoHeading9, li.MsoHeading9, div.MsoHeading9
	{margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:0in;
	text-indent:0in;
	font-size:9.0pt;
	font-family:"Arial",sans-serif;
	font-style:italic;}
p.MsoToc1, li.MsoToc1, div.MsoToc1
	{margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc2, li.MsoToc2, div.MsoToc2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:11.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc3, li.MsoToc3, div.MsoToc3
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:22.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc4, li.MsoToc4, div.MsoToc4
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:33.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc5, li.MsoToc5, div.MsoToc5
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:44.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc6, li.MsoToc6, div.MsoToc6
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:55.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc7, li.MsoToc7, div.MsoToc7
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:66.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc8, li.MsoToc8, div.MsoToc8
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:77.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc9, li.MsoToc9, div.MsoToc9
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:88.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoCommentText, li.MsoCommentText, div.MsoCommentText
	{mso-style-link:"Comment Text Char";
	margin:0in;
	line-height:13.0pt;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
p.MsoHeader, li.MsoHeader, div.MsoHeader
	{mso-style-link:"Header Char";
	margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoFooter, li.MsoFooter, div.MsoFooter
	{mso-style-link:"Footer Char";
	margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoBodyText, li.MsoBodyText, div.MsoBodyText
	{mso-style-link:"Body Text Char";
	margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:green;
	font-style:italic;}
p.MsoBodyText2, li.MsoBodyText2, div.MsoBodyText2
	{mso-style-link:"Body Text 2 Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:0in;
	line-height:200%;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
a:link, span.MsoHyperlink
	{color:blue;
	text-decoration:underline;}
a:visited, span.MsoHyperlinkFollowed
	{color:#954F72;
	text-decoration:underline;}
p.MsoDocumentMap, li.MsoDocumentMap, div.MsoDocumentMap
	{margin:0in;
	background:navy;
	font-size:11.0pt;
	font-family:"Tahoma",sans-serif;}
p.MsoCommentSubject, li.MsoCommentSubject, div.MsoCommentSubject
	{mso-style-link:"Comment Subject Char";
	margin:0in;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.MsoAcetate, li.MsoAcetate, div.MsoAcetate
	{mso-style-link:"Balloon Text Char";
	margin:0in;
	line-height:13.0pt;
	font-size:8.0pt;
	font-family:"Tahoma",sans-serif;}
p.MsoRMPane, li.MsoRMPane, div.MsoRMPane
	{margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.EMEATableCentered, li.EMEATableCentered, div.EMEATableCentered
	{mso-style-name:"EMEA Table Centered";
	margin:0in;
	text-align:center;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.EMEATableLeft, li.EMEATableLeft, div.EMEATableLeft
	{mso-style-name:"EMEA Table Left";
	margin:0in;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.EMEABodyTextIndent, li.EMEABodyTextIndent, div.EMEABodyTextIndent
	{mso-style-name:"EMEA Body Text Indent";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.EMEABodyText, li.EMEABodyText, div.EMEABodyText
	{mso-style-name:"EMEA Body Text";
	mso-style-link:"EMEA Body Text Char";
	margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.EMEATitle, li.EMEATitle, div.EMEATitle
	{mso-style-name:"EMEA Title";
	margin:0in;
	text-align:center;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.EMEAHeading1NoIndent, li.EMEAHeading1NoIndent, div.EMEAHeading1NoIndent
	{mso-style-name:"EMEA Heading 1 No Indent";
	margin:0in;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	text-transform:uppercase;
	font-weight:bold;}
p.EMEAHeading3, li.EMEAHeading3, div.EMEAHeading3
	{mso-style-name:"EMEA Heading 3";
	margin:0in;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.EMEAHeading1, li.EMEAHeading1, div.EMEAHeading1
	{mso-style-name:"EMEA Heading 1";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:28.35pt;
	text-indent:-28.35pt;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	text-transform:uppercase;
	font-weight:bold;}
p.EMEAHeading2, li.EMEAHeading2, div.EMEAHeading2
	{mso-style-name:"EMEA Heading 2";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:28.35pt;
	text-indent:-28.35pt;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.EMEAAddress, li.EMEAAddress, div.EMEAAddress
	{mso-style-name:"EMEA Address";
	margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.EMEAComment, li.EMEAComment, div.EMEAComment
	{mso-style-name:"EMEA Comment";
	margin:0in;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;
	font-style:italic;}
p.EMEAHiddenTitlePIL, li.EMEAHiddenTitlePIL, div.EMEAHiddenTitlePIL
	{mso-style-name:"EMEA Hidden Title PIL";
	margin:0in;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-style:italic;}
p.EMEATitlePAC, li.EMEATitlePAC, div.EMEATitlePAC
	{mso-style-name:"EMEA Title PAC";
	margin:0in;
	page-break-after:avoid;
	border:none;
	padding:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	text-transform:uppercase;
	font-weight:bold;}
span.BMSInstructionText
	{mso-style-name:"BMS Instruction Text";
	font-family:"Times New Roman",serif;
	color:red;
	display:none;
	font-style:italic;
	text-decoration:none none;
	vertical-align:baseline;}
span.EMEASubscript
	{mso-style-name:"EMEA Subscript";
	vertical-align:sub;}
span.EMEASuperscript
	{mso-style-name:"EMEA Superscript";
	vertical-align:super;}
p.EMEATableHeader, li.EMEATableHeader, div.EMEATableHeader
	{mso-style-name:"EMEA Table Header";
	margin:0in;
	text-align:center;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.MemoHeaderStyle, li.MemoHeaderStyle, div.MemoHeaderStyle
	{mso-style-name:MemoHeaderStyle;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:70.9pt;
	text-align:justify;
	font-size:11.0pt;
	font-family:"Arial",sans-serif;
	font-variant:small-caps;
	font-weight:bold;}
span.BodyTextChar
	{mso-style-name:"Body Text Char";
	mso-style-link:"Body Text";
	color:green;
	font-style:italic;}
span.CommentTextChar
	{mso-style-name:"Comment Text Char";
	mso-style-link:"Comment Text";}
p.EMEAEnBodyText, li.EMEAEnBodyText, div.EMEAEnBodyText
	{mso-style-name:"EMEA En Body Text";
	margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:0in;
	text-align:justify;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
span.BalloonTextChar
	{mso-style-name:"Balloon Text Char";
	mso-style-link:"Balloon Text";
	font-family:"Tahoma",sans-serif;}
p.BodytextAgency, li.BodytextAgency, div.BodytextAgency
	{mso-style-name:"Body text \(Agency\)";
	mso-style-link:"Body text \(Agency\) Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:7.0pt;
	margin-left:0in;
	line-height:14.0pt;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;}
span.BodytextAgencyChar
	{mso-style-name:"Body text \(Agency\) Char";
	mso-style-link:"Body text \(Agency\)";
	font-family:"Verdana",sans-serif;}
p.DraftingNotesAgency, li.DraftingNotesAgency, div.DraftingNotesAgency
	{mso-style-name:"Drafting Notes \(Agency\)";
	mso-style-link:"Drafting Notes \(Agency\) Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:7.0pt;
	margin-left:0in;
	line-height:14.0pt;
	font-size:11.0pt;
	font-family:"Courier New";
	color:#339966;
	font-style:italic;}
span.DraftingNotesAgencyChar
	{mso-style-name:"Drafting Notes \(Agency\) Char";
	mso-style-link:"Drafting Notes \(Agency\)";
	font-family:"Courier New";
	color:#339966;
	font-style:italic;}
p.NormalAgency, li.NormalAgency, div.NormalAgency
	{mso-style-name:"Normal \(Agency\)";
	mso-style-link:"Normal \(Agency\) Char";
	margin:0in;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;}
p.TableheadingrowsAgency, li.TableheadingrowsAgency, div.TableheadingrowsAgency
	{mso-style-name:"Table heading rows \(Agency\)";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:7.0pt;
	margin-left:0in;
	line-height:14.0pt;
	page-break-after:avoid;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;
	font-weight:bold;}
p.TabletextrowsAgency, li.TabletextrowsAgency, div.TabletextrowsAgency
	{mso-style-name:"Table text rows \(Agency\)";
	margin:0in;
	line-height:14.0pt;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;}
span.NormalAgencyChar
	{mso-style-name:"Normal \(Agency\) Char";
	mso-style-link:"Normal \(Agency\)";
	font-family:"Verdana",sans-serif;}
span.CommentSubjectChar
	{mso-style-name:"Comment Subject Char";
	mso-style-link:"Comment Subject";
	font-weight:bold;}
span.EMEABodyTextChar
	{mso-style-name:"EMEA Body Text Char";
	mso-style-link:"EMEA Body Text";}
span.FooterChar
	{mso-style-name:"Footer Char";
	mso-style-link:Footer;}
span.CommentTextChar1
	{mso-style-name:"Comment Text Char1";}
p.BMSBodyText, li.BMSBodyText, div.BMSBodyText
	{mso-style-name:"BMS Body Text";
	mso-style-link:"BMS Body Text Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:0in;
	text-align:justify;
	line-height:110%;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.BMSHeading1, li.BMSHeading1, div.BMSHeading1
	{mso-style-name:"BMS Heading 1";
	margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:.8in;
	text-indent:-.8in;
	page-break-after:avoid;
	font-size:12.0pt;
	font-family:"Arial",sans-serif;
	color:black;
	text-transform:uppercase;
	font-weight:bold;}
p.BMSHeading2, li.BMSHeading2, div.BMSHeading2
	{mso-style-name:"BMS Heading 2";
	margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:.8in;
	text-indent:-.8in;
	page-break-after:avoid;
	font-size:12.0pt;
	font-family:"Arial",sans-serif;
	color:black;
	font-weight:bold;}
p.BMSHeading3, li.BMSHeading3, div.BMSHeading3
	{mso-style-name:"BMS Heading 3";
	margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:.8in;
	text-indent:-.8in;
	page-break-after:avoid;
	font-size:12.0pt;
	font-family:"Arial",sans-serif;
	color:black;
	font-weight:bold;
	font-style:italic;}
p.BMSHeading4, li.BMSHeading4, div.BMSHeading4
	{mso-style-name:"BMS Heading 4";
	margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:.8in;
	text-indent:-.8in;
	page-break-after:avoid;
	font-size:12.0pt;
	font-family:"Arial",sans-serif;
	color:black;
	font-weight:bold;
	font-style:italic;}
span.BMSBodyTextChar
	{mso-style-name:"BMS Body Text Char";
	mso-style-link:"BMS Body Text";
	color:black;}
p.BMSTableTitle, li.BMSTableTitle, div.BMSTableTitle
	{mso-style-name:"BMS Table Title";
	mso-style-link:"BMS Table Title Char";
	margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:1.5in;
	text-indent:-1.5in;
	page-break-after:avoid;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
span.BMSTableNote
	{mso-style-name:"BMS Table Note";
	font-family:"Times New Roman",serif;
	color:blue;
	text-decoration:none;
	vertical-align:super;}
p.BMSTableHeader, li.BMSTableHeader, div.BMSTableHeader
	{mso-style-name:"BMS Table Header";
	mso-style-link:"BMS Table Header Char";
	margin-top:3.0pt;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:0in;
	text-align:center;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.BMSTableText, li.BMSTableText, div.BMSTableText
	{mso-style-name:"BMS Table Text";
	mso-style-link:"BMS Table Text Char";
	margin-top:3.0pt;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:0in;
	text-align:center;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
span.BMSTableTextChar
	{mso-style-name:"BMS Table Text Char";
	mso-style-link:"BMS Table Text";}
span.BMSTableHeaderChar
	{mso-style-name:"BMS Table Header Char";
	mso-style-link:"BMS Table Header";
	font-weight:bold;}
span.BMSTableTitleChar
	{mso-style-name:"BMS Table Title Char";
	mso-style-link:"BMS Table Title";
	font-weight:bold;}
span.BMSSuperscript
	{mso-style-name:"BMS Superscript";
	vertical-align:super;}
p.BMSTableNoteInfo, li.BMSTableNoteInfo, div.BMSTableNoteInfo
	{mso-style-name:"BMS Table Note Info";
	mso-style-link:"BMS Table Note Info Char";
	margin-top:2.0pt;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.15in;
	text-align:justify;
	text-indent:-.15in;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
p.BMSTableTextLarge, li.BMSTableTextLarge, div.BMSTableTextLarge
	{mso-style-name:"BMS Table Text Large";
	margin-top:3.0pt;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:0in;
	text-align:center;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.BMSFigureCaption, li.BMSFigureCaption, div.BMSFigureCaption
	{mso-style-name:"BMS Figure Caption";
	margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:1.5in;
	text-indent:-1.5in;
	page-break-after:avoid;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.BMSTableInfo, li.BMSTableInfo, div.BMSTableInfo
	{mso-style-name:"BMS Table Info";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:0in;
	text-align:justify;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
span.BMSTableNoteInfoChar
	{mso-style-name:"BMS Table Note Info Char";
	mso-style-link:"BMS Table Note Info";}
span.BodyText2Char
	{mso-style-name:"Body Text 2 Char";
	mso-style-link:"Body Text 2";}
span.HeaderChar
	{mso-style-name:"Header Char";
	mso-style-link:Header;}
 /* Page Definitions */
 @page WordSection1
	{size:595.35pt 841.95pt;
	margin:56.7pt 70.9pt 56.7pt 70.9pt;}
div.WordSection1
	{page:WordSection1;}
 /* List Definitions */
 ol
	{margin-bottom:0in;}
ul
	{margin-bottom:0in;}
-->
</style>

</head>

<body lang=EN-US link=blue vlink="#954F72" style='word-wrap:break-word'>

<div class=WordSection1>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><i><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></i></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEATitle><span lang=EN-GB>ANNEX I</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEATitle><span lang=EN-GB>SUMMARY OF PRODUCT CHARACTERISTICS</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=EMEABodyText><span lang=EN-GB><img width=21 height=18 id="Picture 1"
src="Nivolumab%20BMS-3840%20-%20EN%20PI%20clea_files/image001.gif"
alt="BT_1000x858px">This medicinal product is subject to additional monitoring.
This will allow quick identification of new safety information. Healthcare
professionals are asked to report any suspected adverse reactions. See
section&nbsp;4.8&nbsp;for how to report adverse reactions.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading1><span lang=EN-GB>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NAME
OF THE MEDICINAL PRODUCT</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Nivolumab&nbsp;BMS&nbsp;10&nbsp;mg/mL
concentrate for solution for infusion.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading1><span lang=EN-GB>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; QUALITATIVE
AND QUANTITATIVE COMPOSITION</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Each mL of concentrate contains&nbsp;10&nbsp;mg
of nivolumab.</span></p>

<p class=EMEABodyText><span lang=EN-GB>One vial of&nbsp;4&nbsp;mL contains&nbsp;40&nbsp;mg
of nivolumab.</span></p>

<p class=EMEABodyText><span lang=EN-GB>One vial of&nbsp;10&nbsp;mL contains&nbsp;100&nbsp;mg
of nivolumab.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Nivolumab is produced in Chinese hamster
ovary cells by recombinant DNA technology.</span></p>

<p class=EMEABodyText><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB>Excipient
with known effect</span></u></p>

<p class=EMEABodyText><span lang=EN-GB>Each mL of concentrate contains&nbsp;0.1&nbsp;mmol
(or&nbsp;2.5&nbsp;mg) sodium.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>For the full list of excipients, see
section&nbsp;6.1.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading1><span lang=EN-GB>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PHARMACEUTICAL
FORM</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Concentrate for solution for infusion
(sterile concentrate).</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Clear to opalescent, colourless to pale
yellow liquid that may contain few light particles. The solution has a pH of approximately&nbsp;6.0
and an osmolality of approximately&nbsp;340&nbsp;mOsm/kg.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading1><span lang=EN-GB>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; CLINICAL
PARTICULARS</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading2><span lang=EN-GB>4.1&nbsp;&nbsp;&nbsp;&nbsp; Therapeutic
indications</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Nivolumab&nbsp;BMS is indicated for the
treatment of locally advanced or metastatic squamous non-small cell lung cancer
(NSCLC) after prior chemotherapy</span><span lang=EN-GB style='color:black;
background:white'> in adults</span><span lang=EN-GB>.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading2><span lang=EN-GB>4.2&nbsp;&nbsp;&nbsp;&nbsp; Posology and
method of administration</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Treatment must be initiated and
supervised by physicians experienced in the treatment of cancer.</span></p>

<p class=EMEABodyText><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB>Posology</span></u></p>

<p class=EMEABodyText><span lang=EN-GB>The recommended dose of Nivolumab&nbsp;BMS
is&nbsp;3&nbsp;mg/kg administered intravenously over&nbsp;60&nbsp;minutes every&nbsp;2&nbsp;weeks.
Treatment should be continued as long as clinical benefit is observed or until treatment
is no longer tolerated by the patient. </span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Dose escalation or reduction is not
recommended. Dosing delay or discontinuation may be required based on
individual safety and tolerability. </span><span lang=EN-GB>Guidelines for
permanent discontinuation or withholding of doses are described in
Table&nbsp;1. Detailed guidelines for the management of immune&#8209;related
adverse reactions are described in section&nbsp;4.4.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0
 style='border-collapse:collapse'>
 <thead>
  <tr>
   <td width=619 colspan=3 valign=top style='width:464.35pt;border:none;
   border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
   <p class=BMSTableTitle><span lang=EN-GB style='font-size:11.0pt'>Table 1:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Recommended
   treatment modifications for Nivolumab&nbsp;BMS</span></p>
   </td>
  </tr>
 </thead>
 <tr>
  <td width=148 valign=top style='width:110.8pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableHeader align=left style='margin:0in;text-align:left;
  page-break-after:avoid'><span lang=EN-GB>Immune-related adverse reaction</span></p>
  </td>
  <td width=236 valign=top style='width:177.35pt;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableHeader align=left style='text-align:left;page-break-after:
  avoid'><span lang=EN-GB>Severity</span></p>
  </td>
  <td width=235 valign=top style='width:176.2pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableHeader align=left style='text-align:left;page-break-after:
  avoid'><span lang=EN-GB>Treatment modification</span></p>
  </td>
 </tr>
 <tr>
  <td width=148 style='width:110.8pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText align=left style='text-align:left;page-break-after:
  avoid'><span lang=EN-GB>Immune&#8209;related pneumonitis</span></p>
  </td>
  <td width=236 valign=top style='width:177.35pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText align=left style='text-align:left;page-break-after:
  avoid'><span lang=EN-GB>Grade&nbsp;2&nbsp;pneumonitis </span></p>
  </td>
  <td width=235 valign=top style='width:176.2pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText align=left style='text-align:left;page-break-after:
  avoid'><span lang=EN-GB>Withhold Nivolumab&nbsp;BMS until symptoms resolve, radiographic
  abnormalities improve, and management with corticosteroids is complete<a
  name=PlaceHolderTableNotes></a></span></p>
  </td>
 </tr>
 <tr>
  <td width=148 style='width:110.8pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText align=left style='text-align:left;page-break-after:
  avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=236 valign=top style='width:177.35pt;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText align=left style='text-align:left;page-break-after:
  avoid'><span lang=EN-GB>Grade&nbsp;3&nbsp;or&nbsp;4&nbsp;pneumonitis</span></p>
  </td>
  <td width=235 valign=top style='width:176.2pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText align=left style='text-align:left;page-break-after:
  avoid'><span lang=EN-GB>Permanently discontinue Nivolumab BMS</span></p>
  </td>
 </tr>
 <tr>
  <td width=148 rowspan=2 style='width:110.8pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText align=left style='text-align:left;page-break-after:
  avoid'><span lang=EN-GB>Immune&#8209;related colitis</span></p>
  </td>
  <td width=236 valign=top style='width:177.35pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText align=left style='text-align:left;page-break-after:
  avoid'><span lang=EN-GB>Grade&nbsp;2&nbsp;or&nbsp;3&nbsp;diarrhoea or colitis</span></p>
  </td>
  <td width=235 valign=top style='width:176.2pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText align=left style='text-align:left;page-break-after:
  avoid'><span lang=EN-GB>Withhold Nivolumab&nbsp;BMS until symptoms resolve
  and management with corticosteroids, if needed, is complete</span></p>
  </td>
 </tr>
 <tr>
  <td width=236 valign=top style='width:177.35pt;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText align=left style='text-align:left;page-break-after:
  avoid'><span lang=EN-GB>Grade&nbsp;4&nbsp;diarrhoea or colitis</span></p>
  </td>
  <td width=235 valign=top style='width:176.2pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText align=left style='text-align:left;page-break-after:
  avoid'><span lang=EN-GB>Permanently discontinue Nivolumab&nbsp;BMS</span></p>
  </td>
 </tr>
 <tr>
  <td width=148 rowspan=2 style='width:110.8pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText align=left style='text-align:left;page-break-after:
  avoid'><span lang=EN-GB>Immune&#8209;related hepatitis</span></p>
  </td>
  <td width=236 valign=top style='width:177.35pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText align=left style='text-align:left;page-break-after:
  avoid'><span lang=EN-GB>Grade&nbsp;2&nbsp;elevation in aspartate
  aminotransferase (AST), alanine aminotransferase (ALT), or total bilirubin </span></p>
  </td>
  <td width=235 valign=top style='width:176.2pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText align=left style='text-align:left;page-break-after:
  avoid'><span lang=EN-GB>Withhold Nivolumab&nbsp;BMS until laboratory values
  return to baseline and management with corticosteroids, if needed, is
  complete</span></p>
  </td>
 </tr>
 <tr>
  <td width=236 valign=top style='width:177.35pt;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText align=left style='text-align:left;page-break-after:
  avoid'><span lang=EN-GB>Grade&nbsp;3&nbsp;or&nbsp;4&nbsp;elevation in AST,
  ALT, or total bilirubin </span></p>
  </td>
  <td width=235 valign=top style='width:176.2pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText align=left style='text-align:left;page-break-after:
  avoid'><span lang=EN-GB>Permanently discontinue Nivolumab&nbsp;BMS</span></p>
  </td>
 </tr>
 <tr>
  <td width=148 rowspan=2 style='width:110.8pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText align=left style='text-align:left;page-break-after:
  avoid'><span lang=EN-GB>Immune&#8209;related nephritis and renal dysfunction</span></p>
  </td>
  <td width=236 valign=top style='width:177.35pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText align=left style='text-align:left;page-break-after:
  avoid'><span lang=EN-GB>Grade&nbsp;2&nbsp;or&nbsp;3&nbsp;creatinine elevation
  </span></p>
  </td>
  <td width=235 valign=top style='width:176.2pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText align=left style='text-align:left;page-break-after:
  avoid'><span lang=EN-GB>Withhold Nivolumab&nbsp;BMS until creatinine returns
  to baseline and management with corticosteroids is complete</span></p>
  </td>
 </tr>
 <tr>
  <td width=236 valign=top style='width:177.35pt;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText align=left style='text-align:left;page-break-after:
  avoid'><span lang=EN-GB>Grade&nbsp;4&nbsp;creatinine elevation</span></p>
  </td>
  <td width=235 valign=top style='width:176.2pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText align=left style='text-align:left;page-break-after:
  avoid'><span lang=EN-GB>Permanently discontinue Nivolumab&nbsp;BMS</span></p>
  </td>
 </tr>
 <tr>
  <td width=148 style='width:110.8pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText align=left style='text-align:left;page-break-after:
  avoid'><span lang=EN-GB>Immune&#8209;related endocrinopathies</span></p>
  </td>
  <td width=236 valign=top style='width:177.35pt;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText align=left style='text-align:left;page-break-after:
  avoid'><span lang=EN-GB>Symptomatic endocrinopathies (including
  hypothyroidism, hyperthyroidism, hypophysitis, adrenal insufficiency and
  diabetes)</span></p>
  </td>
  <td width=235 valign=top style='width:176.2pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText align=left style='text-align:left;page-break-after:
  avoid'><span lang=EN-GB>Withhold Nivolumab&nbsp;BMS until symptoms resolve
  and management with corticosteroids (if needed for symptoms of acute
  inflammation) is complete. Nivolumab&nbsp;BMS should be continued in the
  presence of hormone replacement therapy<sup>a</sup> as long as no symptoms
  are present</span></p>
  </td>
 </tr>
 <tr>
  <td width=148 style='width:110.8pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText align=left style='text-align:left;page-break-after:
  avoid'><span lang=FR-BE>Immune</span><span lang=EN-GB>&#8209;</span><span
  lang=FR-BE>related rash</span></p>
  </td>
  <td width=236 valign=top style='width:177.35pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText align=left style='text-align:left;page-break-after:
  avoid'><span lang=FR-BE>Grade&nbsp;3 rash</span></p>
  </td>
  <td width=235 valign=top style='width:176.2pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText align=left style='margin:0in;text-align:left;
  page-break-after:avoid'>Withhold dose until symptoms resolve and management
  with corticosteroids is complete</p>
  <p class=BMSTableText align=left style='text-align:left;page-break-after:
  avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=148 style='width:110.8pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText align=left style='text-align:left;page-break-after:
  avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=236 valign=top style='width:177.35pt;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText align=left style='text-align:left;page-break-after:
  avoid'><span lang=FR-BE>Grade&nbsp;4 rash</span></p>
  </td>
  <td width=235 valign=top style='width:176.2pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText align=left style='text-align:left;page-break-after:
  avoid'><span lang=FR-BE>Permanently discontinue </span><span lang=EN-GB>Nivolumab&nbsp;BMS</span></p>
  </td>
 </tr>
</table>

<p class=EMEABodyText style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-size:10.0pt'>Note: Toxicity grades are in accordance
with National Cancer Institute Common Terminology Criteria for Adverse Events
Version&nbsp;4.0&nbsp;(NCI&#8209;CTCAE v4).</span></p>

<p class=BMSBodyText align=left style='margin-bottom:0in;text-align:left;
line-height:normal'><span class=EMEASuperscript><span lang=EN-GB
style='font-size:11.0pt'>a</span></span><span lang=EN-GB style='font-size:10.0pt'>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Recommendation for the
use of hormone replacement therapy is provided in section 4.4.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Nivolumab&nbsp;BMS should also be
permanently discontinued for Grade&nbsp;2&nbsp;or&nbsp;3&nbsp;immune&#8209;related
adverse reactions that persist despite treatment modifications (see
section&nbsp;4.4) or for inability to reduce corticosteroid dose
to&nbsp;10&nbsp;mg prednisone or equivalent per day.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Patients treated with Nivolumab&nbsp;BMS
must be given the patient alert card and be informed about the risks of
Nivolumab&nbsp;BMS (see also package leaflet).</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><i><u><span lang=EN-GB>Special
populations</span></u></i></p>

<p class=EMEABodyText style='page-break-after:avoid'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=EMEABodyText style='page-break-after:avoid'><i><span lang=EN-GB>Paediatric
population</span></i></p>

<p class=EMEABodyText><span lang=EN-GB>The safety and efficacy of
Nivolumab&nbsp;BMS in children below&nbsp;18&nbsp;years of age have not been
established. No data are available.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><i><span lang=EN-GB>Elderly
</span></i></p>

<p class=EMEABodyText><span lang=EN-GB>No dose adjustment is required for elderly
patients (&#8805;&nbsp;65&nbsp;years) (see sections&nbsp;5.1 and&nbsp;5.2). Data
from patients 75&nbsp;years of age or older are too limited to draw conclusions
on this population.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><i><span lang=EN-GB>Renal
impairment</span></i></p>

<p class=EMEABodyText><span lang=EN-GB>Based on the population pharmacokinetic
(PK) results, no dose adjustment is required in patients with mild or moderate renal
impairment (see section&nbsp;5.2). Data from patients with severe renal
impairment are too limited to draw conclusions on this population.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><i><span lang=EN-GB>Hepatic
impairment</span></i></p>

<p class=EMEABodyText><span lang=EN-GB>Based on the population PK results, no
dose adjustment is required in patients with mild hepatic impairment (see
section&nbsp;5.2). </span><span lang=EN-GB>Data from patients with moderate or
severe hepatic impairment are too limited to draw conclusions on these
populations. </span><span lang=EN-GB>Nivolumab&nbsp;BMS</span><span lang=EN-GB
style='font-size:11.5pt'> must be administered with caution in patients with
moderate (total
bilirubin&nbsp;&gt;&nbsp;1.5&nbsp;&times;&nbsp;to&nbsp;3&nbsp;&times;&nbsp;the
upper limit of normal [ULN] and any AST) or severe (total
bilirubin&nbsp;&gt;&nbsp;3&nbsp;&times;&nbsp;ULN and any AST) hepatic
impairment.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB>Method
of administration </span></u></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Nivolumab&nbsp;BMS is for intravenous
use only. It is to be administered as an intravenous infusion over a period of&nbsp;60&nbsp;minutes.
The infusion must be administered through a sterile, non&#8209;pyrogenic, low
protein binding in&#8209;line filter with a pore size of&nbsp;0.2&#8209;1.2&nbsp;</span><span
lang=EN-GB style='font-family:Symbol'>m</span><span lang=EN-GB>m.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Nivolumab&nbsp;BMS must not be
administered as an intravenous push or bolus injection.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>The total dose of Nivolumab&nbsp;BMS required
can be infused directly as a&nbsp;10&nbsp;mg/mL solution or can be diluted to
as low as&nbsp;1&nbsp;mg/mL with sodium chloride&nbsp;9&nbsp;mg/mL (0.9%)
solution for injection or&nbsp;glucose 50&nbsp;mg/mL (5%) solution for
injection. </span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>For instructions on the handling of the
medicinal product before administration, see section&nbsp;6.6.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading2><span lang=EN-GB>4.3&nbsp;&nbsp;&nbsp;&nbsp; Contraindications</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Hypersensitivity to the active substance
or to any of the excipients listed in section&nbsp;6.1.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading2><span lang=EN-GB>4.4&nbsp;&nbsp;&nbsp;&nbsp; Special
warnings and precautions for use</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Nivolumab is associated with immune&#8209;related
adverse reactions. Patients should be monitored continuously (at least up to
5&nbsp;months after the last dose) as an adverse reaction with nivolumab may
occur at any time during or after discontinuation of nivolumab therapy. </span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>For suspected immune-related adverse
reactions, adequate evaluation should be performed to confirm aetiology or
exclude other causes. Based on the severity of the adverse reaction, nivolumab
should be withheld and corticosteroids administered. If immunosuppression with
corticosteroids is used to treat an adverse reaction, a taper of at
least&nbsp;1&nbsp;month duration should be initiated upon improvement. Rapid
tapering may lead to worsening of the adverse reaction. Non&#8209;corticosteroid
immunosuppressive therapy should be added if there is worsening or no
improvement despite corticosteroid use. </span></p>

<p class=EMEABodyText><span lang=EN-GB>Nivolumab should not be resumed while
the patient is receiving immunosuppressive doses of corticosteroids or other
immunosuppressive therapy. Prophylactic antibiotics should be used to prevent
opportunistic infections in patients receiving immunosuppressive therapy.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Nivolumab must be permanently discontinued
for any severe immune related adverse reaction that recurs and for any life
threatening immune related adverse reaction.</span></p>

<p class=EMEABodyText><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB>Immune&#8209;related
pneumonitis</span></u></p>

<p class=EMEABodyText><span lang=EN-GB>Severe pneumonitis or interstitial lung
disease, including fatal cases, has been observed with nivolumab treatment (see
section&nbsp;4.8). Patients should be monitored for signs and symptoms of
pneumonitis such as radiographic changes (e.g., focal ground glass opacities,
patchy filtrates), dyspnoea, and hypoxia. Infectious and disease&#8209;related
aetiologies should be ruled out.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>For
Grade&nbsp;3&nbsp;or&nbsp;4&nbsp;pneumonitis, nivolumab must be permanently
discontinued, and corticosteroids should be initiated at a dose
of&nbsp;2&nbsp;to&nbsp;4&nbsp;mg/kg/day methylprednisolone equivalents.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>For Grade&nbsp;2&nbsp;(symptomatic)
pneumonitis, nivolumab should be withheld and corticosteroids initiated at a
dose of&nbsp;1&nbsp;mg/kg/day methylprednisolone equivalents. Upon improvement,
nivolumab may be resumed after corticosteroid taper. If worsening or no
improvement occurs despite initiation of corticosteroids, corticosteroid dose
should be increased to&nbsp;2&nbsp;to&nbsp;4&nbsp;mg/kg/day methylprednisolone
equivalents and nivolumab must be permanently discontinued.</span></p>

<p class=EMEABodyText><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB>Immune&#8209;related
colitis</span></u></p>

<p class=EMEABodyText><span lang=EN-GB>Severe diarrhoea or colitis has been
observed with nivolumab treatment (see section&nbsp;4.8). Patients should be monitored
for diarrhoea and additional symptoms of colitis, such as abdominal pain and
mucus or blood in stool. Infectious and disease&#8209;related aetiologies
should be ruled out. </span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>For Grade&nbsp;4&nbsp;diarrhoea or
colitis, nivolumab must be permanently discontinued, and corticosteroids should
be initiated at a dose of&nbsp;1&nbsp;to&nbsp;2&nbsp;mg/kg/day
methylprednisolone equivalents.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>For Grade&nbsp;3&nbsp;diarrhoea or
colitis, nivolumab should be withheld and corticosteroids initiated at a dose
of&nbsp;1&nbsp;to&nbsp;2&nbsp;mg/kg/day methylprednisolone equivalents. Upon
improvement, nivolumab may be resumed after corticosteroid taper. If worsening
or no improvement occurs despite initiation of corticosteroids, nivolumab must
be permanently discontinued.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>For Grade&nbsp;2&nbsp;diarrhoea or
colitis, nivolumab should be withheld. Persistent diarrhoea or colitis should
be managed with corticosteroids at a dose
of&nbsp;0.5&nbsp;to&nbsp;1&nbsp;mg/kg/day methylprednisolone equivalents. Upon
improvement, nivolumab may be resumed after corticosteroid taper, if needed. If
worsening or no improvement occurs despite initiation of corticosteroids,
corticosteroid dose should be increased to&nbsp;1&nbsp;to&nbsp;2&nbsp;mg/kg/day
methylprednisolone equivalents and nivolumab must be permanently discontinued.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB>Immune&#8209;related
hepatitis</span></u></p>

<p class=EMEABodyText><span lang=EN-GB>Severe hepatitis has been observed with
nivolumab treatment. Patients should be monitored for signs and symptoms of
hepatitis such as transaminase and total bilirubin elevations. Infectious and
disease&#8209;related aetiologies should be ruled out.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>For
Grade&nbsp;3&nbsp;or&nbsp;4&nbsp;transaminase or total bilirubin elevation, nivolumab
must be permanently discontinued, and corticosteroids should be initiated at a
dose of&nbsp;1&nbsp;to&nbsp;2&nbsp;mg/kg/day methylprednisolone equivalents.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>For Grade&nbsp;2&nbsp;transaminase or
total bilirubin elevation, nivolumab should be withheld. Persistent elevations
in these laboratory values should be managed with corticosteroids at a dose
of&nbsp;0.5&nbsp;to&nbsp;1&nbsp;mg/kg/day methylprednisolone equivalents. Upon
improvement, nivolumab may be resumed after corticosteroid taper, if needed. If
worsening or no improvement occurs despite initiation of corticosteroids,
corticosteroid dose should be increased to&nbsp;1&nbsp;to&nbsp;2&nbsp;mg/kg/day
methylprednisolone equivalents and nivolumab must be permanently discontinued.</span></p>

<p class=EMEABodyText><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB>Immune&#8209;related
nephritis or renal dysfunction</span></u></p>

<p class=EMEABodyText><span lang=EN-GB>Severe nephritis or renal dysfunction
has been observed with nivolumab treatment (see section&nbsp;4.8). Patients
should be monitored for signs and symptoms of nephritis and renal dysfunction.
Most patients present with asymptomatic increases in serum creatinine. Disease&#8209;related
aetiologies should be ruled out.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>For Grade&nbsp;4&nbsp;serum creatinine
elevation, nivolumab must be permanently discontinued, and corticosteroids
should be initiated at a dose of&nbsp;1&nbsp;to&nbsp;2&nbsp;mg/kg/day
methylprednisolone equivalents.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>For
Grade&nbsp;2&nbsp;or&nbsp;3&nbsp;serum creatinine elevation, nivolumab should
be withheld, and corticosteroids should be initiated at a dose
of&nbsp;0.5&nbsp;to&nbsp;1&nbsp;mg/kg/day methylprednisolone equivalents. Upon
improvement, nivolumab may be resumed after corticosteroid taper. If worsening
or no improvement occurs despite initiation of corticosteroids, corticosteroid
dose should be increased to&nbsp;1&nbsp;to&nbsp;2&nbsp;mg/kg/day
methylprednisolone equivalents, and nivolumab must be permanently discontinued.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB>Immune&#8209;related
endocrinopathies</span></u></p>

<p class=EMEABodyText><span lang=EN-GB>Severe endocrinopathies, including
hypothyroidism, hyperthyroidism, adrenal insufficiency, hypophysitis, diabetes
mellitus, and diabetic ketoacidosis have been observed with nivolumab treatment.
</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText>Patients should be monitored for clinical signs and
symptoms of endocrinopathies and for changes in thyroid function (at the start
of treatment, periodically during treatment, and as indicated based on clinical
evaluation). Patients may present with fatigue, headache, mental status
changes, abdominal pain, unusual bowel habits, and hypotension, or nonspecific
symptoms which may resemble other causes such as brain metastasis or underlying
disease. Unless an alternate etiology has been identified, signs or symptoms of
endocrinopathies should be considered immune-related.</p>

<p class=EMEABodyText><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=EMEABodyText><span lang=EN-GB>For symptomatic hypothyroidism,
nivolumab should be withheld, and thyroid hormone replacement should be
initiated as needed. For symptomatic hyperthyroidism, nivolumab should be
withheld and methimazole should be initiated as needed. Corticosteroids at a
dose of&nbsp;1&nbsp;to&nbsp;2&nbsp;mg/kg/day methylprednisolone equivalents
should also be considered if acute inflammation of the thyroid is suspected.
Upon improvement, nivolumab may be resumed after corticosteroid taper, if
needed. Monitoring of thyroid function should continue to ensure appropriate
hormone replacement is utilised.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>For symptomatic adrenal insufficiency,
nivolumab should be withheld, and physiologic corticosteroid replacement should
be initiated as needed. Monitoring of adrenal function and hormone levels
should continue to ensure appropriate corticosteroid replacement is utilised.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>For symptomatic hypophysitis, nivolumab
should be withheld, and hormone replacement should be initiated as needed.
Corticosteroids at a dose of 1&nbsp;to 2&nbsp;mg/kg/day methylprednisolone
equivalents should also be considered if acute inflammation of the pituitary
gland is suspected. Upon improvement, nivolumab may be resumed after
corticosteroid taper, if needed. Monitoring of pituitary function and hormone
levels should continue to ensure appropriate hormone replacement is utilised.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>For symptomatic diabetes, nivolumab
should be withheld, and insulin replacement should be initiated as needed.
Monitoring of blood sugar should continue to ensure appropriate insulin
replacement is utilised. </span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB>Immune-related rash</span></u></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Severe
rash has been observed with nivolumab treatment that may be immune-related (see
section&nbsp;4.8). Nivolumab should be withheld for Grade&nbsp;3 rash and
discontinued for Grade&nbsp;4 rash. Severe rash should be managed with
high-dose corticosteroid at a dose of 1&nbsp;to 2&nbsp;mg/kg/day prednisone
equivalents. </span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText>Caution should be used when considering the use of nivolumab
in a patient who has previously experienced a severe or life-threatening skin
adverse reaction on prior treatment with other immune-stimulatory anticancer
agents.</p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB>Other
immune&#8209;related adverse reactions</span></u></p>

<p class=BMSBodyText style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-size:11.0pt'>The following immune-related adverse
reactions were reported in less than 1% of patients treated with nivolumab in
clinical trials across doses and tumour types: pancreatitis, uveitis,
demyelination, autoimmune neuropathy (including facial and abducens nerve
paresis), Guillain&#8209;Barr&eacute; syndrome, hypopituitarism, and</span><span
lang=EN-GB> </span><span lang=EN-GB style='font-size:11.0pt'>myasthenic
syndrome</span><span lang=EN-GB>.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>For suspected immune&#8209;related
adverse reactions, adequate evaluation should be performed to confirm aetiology
or exclude other causes. Based on the severity of the adverse reaction,
nivolumab should be withheld and corticosteroids administered. Upon
improvement, nivolumab may be resumed after corticosteroid taper. Nivolumab
must be permanently discontinued for any severe immune&#8209;related adverse
reaction that recurs and for any life&#8209;threatening immune&#8209;related
adverse reaction.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB>Infusion
reactions</span></u></p>

<p class=EMEABodyText><span lang=EN-GB>Severe infusion reactions have been
reported in clinical trials (see section&nbsp;4.8). In case of a severe
infusion reaction, nivolumab infusion must be discontinued and appropriate medical
therapy administered. Patients with mild or moderate infusion reaction may
receive nivolumab with close monitoring.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB>Special
populations </span></u></p>

<p class=EMEABodyText><span lang=EN-GB>Patients with a baseline performance
score&nbsp;&#8805;&nbsp;2, active brain metastases or autoimmune disease,
symptomatic interstitial lung disease, and patients who had been receiving
systemic immunosuppressants prior to study entry were excluded from the clinical
trials of NSCLC (see sections 4.5 and&nbsp;5.1).</span><span lang=EN-GB> </span><span
lang=EN-GB>In the absence of data, nivolumab should be used with caution in
these populations after careful consideration of the potential risk-benefit on
an individual basis.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB>Patients
on controlled sodium diet</span></u></p>

<p class=EMEABodyText><span lang=EN-GB>Each mL of this medicinal product
contains&nbsp;0.1&nbsp;mmol (or&nbsp;2.5&nbsp;mg) sodium. To be taken into
consideration when treating patients on a controlled sodium diet.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Patient Alert Card</span></p>

<p class=EMEABodyText><span lang=EN-GB>All prescribers of Nivolumab&nbsp;BMS
must be familiar with the Physician Information and Management Guidelines. The
prescriber must discuss the risks of Nivolumab&nbsp;BMS therapy with the
patient. The patient will be provided with the Patient Alert Card with each
prescription.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading2><span lang=EN-GB>4.5&nbsp;&nbsp;&nbsp;&nbsp; Interaction
with other medicinal products and other forms of interaction</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Nivolumab is a human monoclonal
antibody,</span><span lang=EN-GB> as such pharmacokinetic interaction studies
have not been conducted. As monoclonal antibodies are not metabolised by
cytochrome P450 (CYP) enzymes or other drug metabolising enzymes, inhibition or
induction of these enzymes by co&#8209;administered medicinal products is not
anticipated to affect the pharmacokinetics of nivolumab. </span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB>Other
forms of interaction </span></u></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><i><u><span lang=EN-GB>Systemic
immunosuppression</span></u></i></p>

<p class=EMEABodyText><span lang=EN-GB>The use of systemic corticosteroids and
other immunosuppressants at baseline, before starting nivolumab, should be
avoided because of their potential interference with the pharmacodynamic
activity. However, systemic corticosteroids and other immunosuppressants can be
used after starting nivolumab to treat immune&#8209;related adverse reactions.
The preliminary results show that systemic immunosuppression after starting
nivolumab treatment does not appear to preclude the response on nivolumab.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading2><span lang=EN-GB>4.6&nbsp;&nbsp;&nbsp;&nbsp; Fertility,
pregnancy and lactation</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB>Pregnancy</span></u></p>

<p class=EMEABodyText><span lang=EN-GB>There are no data on the use of
nivolumab in pregnant women. Studies in animals have shown embryofoetal toxicity
(see section&nbsp;5.3). Human IgG4 is known to cross the placental barrier and
nivolumab is an IgG4; therefore nivolumab has the potential to be transmitted
from the mother to the developing foetus. Nivolumab is not recommended during
pregnancy and in women of childbearing potential not using effective contraception
</span><span lang=EN-GB>unless the clinical benefit outweighs the potential
risk</span><span lang=EN-GB>. Effective contraception should be used for at
least 5&nbsp;months following the last dose of Nivolumab&nbsp;BMS.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB>Breast&#8209;feeding</span></u></p>

<p class=EMEABodyText><span lang=EN-GB>It is unknown whether nivolumab is
secreted in human milk. </span><span lang=EN-GB style='color:black'>Because many
medicinal products, including antibodies, can be secreted in human milk, a</span><span
lang=EN-GB> risk to the ne</span><span lang=EN-GB>wborns/infants cannot be
excluded. A decision must be made whether to discontinue breast&#8209;feeding
or to discontinue from nivolumab therapy taking into account the benefit of breast&#8209;feeding
for the child and the benefit of therapy for the woman.</span></p>

<p class=EMEABodyText><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB>Fertility</span></u></p>

<p class=EMEABodyText><span lang=EN-GB>Studies to evaluate the effect of
nivolumab on fertility have not been performed. Thus, the effect of nivolumab
on male and female fertility is unknown.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading2><span lang=EN-GB>4.7&nbsp;&nbsp;&nbsp;&nbsp; Effects on
ability to drive and use machines</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Based on its pharmacodynamic properties,
nivolumab is unlikely to affect the ability to drive and use machines. Because
of potential adverse reactions such as fatigue (see section&nbsp;4.8), patients
should be advised to use caution when driving or operating machinery until they
are certain that nivolumab does not adversely affect them.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading2><span lang=EN-GB>4.8&nbsp;&nbsp;&nbsp;&nbsp; Undesirable
effects</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB>Summary
of the safety profile</span></u></p>

<p class=EMEABodyText><span lang=EN-GB>Nivolumab is most commonly associated
with immune-related adverse reactions. Most of these, including severe
reactions, resolved following initiation of appropriate medical therapy or
withdrawal of nivolumab (see &#8220;Description of selected adverse
reactions&#8221; below).</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>In the pooled dataset of two studies in squamous
NSCLC (CA209017 and CA209063), the most frequent adverse reactions
(&#8805;&nbsp;10%&nbsp;of patients) were fatigue (33%), decreased appetite
(15%), and nausea (12%). </span><span lang=EN-GB>The majority of adverse
reactions were mild to moderate (Grade&nbsp;1&nbsp;or&nbsp;2)</span><span
lang=EN-GB>. </span></p>

<p class=EMEABodyText><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB>Tabulated
summary of adverse reactions</span></u></p>

<p class=EMEABodyText><span lang=EN-GB>Adverse reactions reported in the pooled
dataset (n=248) of CA209017 and CA209063 are presented in Table&nbsp;2. These
reactions are presented by system organ class and by frequency. Frequencies are
defined as: very common (&#8805;&nbsp;1/10); common (&#8805;&nbsp;1/100&nbsp;to&nbsp;&lt;&nbsp;1/10);
uncommon&nbsp;(&#8805;&nbsp;1/1,000&nbsp;to&nbsp;&lt;&nbsp;1/100);
rare&nbsp;(&#8805;&nbsp;1/10,000&nbsp;to&nbsp;&lt;&nbsp;1/1,000); very
rare&nbsp;(&lt;&nbsp;1/10,000). </span><span lang=EN-GB>Within each frequency
grouping, adverse reactions are presented in the order of decreasing
seriousness.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=624
 style='width:467.8pt;margin-left:5.4pt;border-collapse:collapse'>
 <tr style='height:29.4pt'>
  <td width=624 colspan=2 style='width:467.8pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:29.4pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><b><span lang=EN-GB>Table
  2: </span></b><b><span lang=EN-GB>Adverse reactions in patients with squamous
  NSCLC treated with nivolumab&nbsp;3&nbsp;mg/kg (CA209017 and CA209063)</span></b></p>
  </td>
 </tr>
 <tr style='height:14.15pt'>
  <td width=624 colspan=2 valign=top style='width:467.8pt;border:solid windowtext 1.0pt;
  border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:14.15pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><b><span lang=EN-GB
  style='color:black'>Infections and infestations</span></b></p>
  </td>
 </tr>
 <tr style='height:13.45pt'>
  <td width=138 valign=top style='width:103.7pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Uncommon</span></p>
  </td>
  <td width=485 valign=top style='width:364.1pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
  style='letter-spacing:.15pt'>bronchitis, upper respiratory tract infection</span></p>
  </td>
 </tr>
 <tr style='height:14.15pt'>
  <td width=624 colspan=2 valign=top style='width:467.8pt;border:solid windowtext 1.0pt;
  border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:14.15pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><b><span lang=EN-GB
  style='color:black'>Neoplasms benign, malignant and unspecified (including
  cysts and polyps)</span></b></p>
  </td>
 </tr>
 <tr style='height:13.45pt'>
  <td width=138 valign=top style='width:103.7pt;border:solid windowtext 1.0pt;
  border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
  style='color:black'>Uncommon</span></p>
  </td>
  <td width=485 valign=top style='width:364.1pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
  style='color:black'>histocytic necrotising lymphadenitis (Kikuchi
  lymphadenitis)</span></p>
  </td>
 </tr>
 <tr style='height:13.45pt'>
  <td width=624 colspan=2 valign=top style='width:467.8pt;border:solid windowtext 1.0pt;
  border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><b><span lang=EN-GB
  style='color:black'>Immune system disorders</span></b></p>
  </td>
 </tr>
 <tr style='height:13.45pt'>
  <td width=138 valign=top style='width:103.7pt;border:solid windowtext 1.0pt;
  border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
  style='color:black'>Uncommon</span></p>
  </td>
  <td width=485 valign=top style='width:364.1pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
  style='color:black;letter-spacing:.15pt'>anaphylactic reaction, hypersensitivity,
  infusion related reaction </span></p>
  </td>
 </tr>
 <tr style='height:13.45pt'>
  <td width=624 colspan=2 valign=top style='width:467.8pt;border:solid windowtext 1.0pt;
  border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><b><span lang=EN-GB
  style='color:black'>Endocrine disorders</span></b></p>
  </td>
 </tr>
 <tr style='height:13.45pt'>
  <td width=138 valign=top style='width:103.7pt;border:solid windowtext 1.0pt;
  border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
  style='color:black'>Common</span></p>
  </td>
  <td width=485 valign=top style='width:364.1pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
  style='color:black;letter-spacing:.15pt'>hypothyroidism</span></p>
  </td>
 </tr>
 <tr style='height:13.45pt'>
  <td width=138 valign=top style='width:103.7pt;border:solid windowtext 1.0pt;
  border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
  style='color:black'>Uncommon</span></p>
  </td>
  <td width=485 valign=top style='width:364.1pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
  style='color:black;letter-spacing:.15pt'>adrenal insufficiency, thyroiditis </span></p>
  </td>
 </tr>
 <tr style='height:14.15pt'>
  <td width=624 colspan=2 valign=top style='width:467.8pt;border:solid windowtext 1.0pt;
  border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:14.15pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><b><span lang=EN-GB
  style='color:black'>Metabolism and nutrition disorders</span></b></p>
  </td>
 </tr>
 <tr style='height:13.45pt'>
  <td width=138 valign=top style='width:103.7pt;border:solid windowtext 1.0pt;
  border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
  style='color:black'>Very common</span></p>
  </td>
  <td width=485 valign=top style='width:364.1pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
  style='color:black;letter-spacing:.15pt'>decreased appetite</span></p>
  </td>
 </tr>
 <tr style='height:14.15pt'>
  <td width=624 colspan=2 valign=top style='width:467.8pt;border:solid windowtext 1.0pt;
  border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:14.15pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><b><span lang=EN-GB
  style='color:black'>Nervous system disorders</span></b><span lang=EN-GB
  style='color:black;letter-spacing:.15pt'> </span></p>
  </td>
 </tr>
 <tr style='height:13.45pt'>
  <td width=138 valign=top style='width:103.7pt;border:solid windowtext 1.0pt;
  border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
  style='color:black'>Common</span></p>
  </td>
  <td width=485 valign=top style='width:364.1pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
  style='color:black;letter-spacing:.15pt'>peripheral neuropathy, headache,
  dizziness</span></p>
  </td>
 </tr>
 <tr style='height:13.45pt'>
  <td width=138 valign=top style='width:103.7pt;border:solid windowtext 1.0pt;
  border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
  style='color:black'>Uncommon</span></p>
  </td>
  <td width=485 valign=top style='width:364.1pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
  style='color:black;letter-spacing:.15pt'>myasthenic syndrome, polyneuropathy</span></p>
  </td>
 </tr>
 <tr style='height:14.15pt'>
  <td width=624 colspan=2 valign=top style='width:467.8pt;border:solid windowtext 1.0pt;
  border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:14.15pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><b><span lang=EN-GB
  style='color:black'>Cardiac disorders</span></b></p>
  </td>
 </tr>
 <tr style='height:13.45pt'>
  <td width=138 valign=top style='width:103.7pt;border:solid windowtext 1.0pt;
  border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
  style='color:black'>Uncommon</span></p>
  </td>
  <td width=485 valign=top style='width:364.1pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
  style='color:black;letter-spacing:.15pt'>tachycardia</span></p>
  </td>
 </tr>
 <tr style='height:14.15pt'>
  <td width=624 colspan=2 valign=top style='width:467.8pt;border:solid windowtext 1.0pt;
  border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:14.15pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><b><span lang=EN-GB
  style='color:black'>Vascular disorders</span></b></p>
  </td>
 </tr>
 <tr style='height:13.45pt'>
  <td width=138 valign=top style='width:103.7pt;border:solid windowtext 1.0pt;
  border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
  style='color:black'>Uncommon</span></p>
  </td>
  <td width=485 valign=top style='width:364.1pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
  style='color:black;letter-spacing:.15pt'>vasculitis</span></p>
  </td>
 </tr>
 <tr style='height:14.15pt'>
  <td width=624 colspan=2 valign=top style='width:467.8pt;border:solid windowtext 1.0pt;
  border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:14.15pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><b><span lang=EN-GB
  style='color:black'>Respiratory, thoracic and mediastinal disorders</span></b></p>
  </td>
 </tr>
 <tr style='height:13.45pt'>
  <td width=138 valign=top style='width:103.7pt;border:solid windowtext 1.0pt;
  border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
  style='color:black'>Common</span></p>
  </td>
  <td width=485 valign=top style='width:364.1pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
  style='color:black;letter-spacing:.15pt'>pneumonitis, dyspnoea, cough</span></p>
  </td>
 </tr>
 <tr style='height:13.45pt'>
  <td width=138 valign=top style='width:103.7pt;border:solid windowtext 1.0pt;
  border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
  style='color:black'>Uncommon</span></p>
  </td>
  <td width=485 valign=top style='width:364.1pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
  style='color:black;letter-spacing:.15pt'>lung infiltration</span></p>
  </td>
 </tr>
 <tr style='height:14.15pt'>
  <td width=624 colspan=2 valign=top style='width:467.8pt;border:solid windowtext 1.0pt;
  border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:14.15pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><b><span lang=EN-GB
  style='color:black'>Gastrointestinal disorders</span></b></p>
  </td>
 </tr>
 <tr style='height:13.45pt'>
  <td width=138 valign=top style='width:103.7pt;border:solid windowtext 1.0pt;
  border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
  style='color:black'>Very common</span></p>
  </td>
  <td width=485 valign=top style='width:364.1pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
  style='color:black;letter-spacing:.15pt'>nausea</span></p>
  </td>
 </tr>
 <tr style='height:13.45pt'>
  <td width=138 valign=top style='width:103.7pt;border:solid windowtext 1.0pt;
  border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
  style='color:black'>Common</span></p>
  </td>
  <td width=485 valign=top style='width:364.1pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
  style='color:black;letter-spacing:.15pt'>diarrhoea, stomatitis, vomiting, abdominal
  pain, constipation, dry mouth</span></p>
  </td>
 </tr>
 <tr style='height:13.45pt'>
  <td width=138 valign=top style='width:103.7pt;border:solid windowtext 1.0pt;
  border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
  style='color:black'>Uncommon</span></p>
  </td>
  <td width=485 valign=top style='width:364.1pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
  style='color:black;letter-spacing:.15pt'>colitis, duodenal ulcer</span></p>
  </td>
 </tr>
 <tr style='height:14.15pt'>
  <td width=624 colspan=2 valign=top style='width:467.8pt;border:solid windowtext 1.0pt;
  border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:14.15pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><b><span lang=EN-GB
  style='color:black'>Skin and subcutaneous tissue disorders</span></b></p>
  </td>
 </tr>
 <tr style='height:13.45pt'>
  <td width=138 valign=top style='width:103.7pt;border:solid windowtext 1.0pt;
  border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
  style='color:black'>Common</span></p>
  </td>
  <td width=485 valign=top style='width:364.1pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
  style='color:black;letter-spacing:.15pt'>rash, pruritus</span></p>
  </td>
 </tr>
 <tr style='height:13.45pt'>
  <td width=138 valign=top style='width:103.7pt;border:solid windowtext 1.0pt;
  border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
  style='color:black'>Uncommon</span></p>
  </td>
  <td width=485 valign=top style='width:364.1pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
  style='color:black;letter-spacing:.15pt'>urticaria</span></p>
  </td>
 </tr>
 <tr style='height:14.15pt'>
  <td width=624 colspan=2 valign=top style='width:467.8pt;border:solid windowtext 1.0pt;
  border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:14.15pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><b><span lang=EN-GB
  style='color:black'>Musculoskeletal and connective tissue disorders</span></b></p>
  </td>
 </tr>
 <tr style='height:13.45pt'>
  <td width=138 valign=top style='width:103.7pt;border:solid windowtext 1.0pt;
  border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
  style='color:black'>Common</span></p>
  </td>
  <td width=485 valign=top style='width:364.1pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
  style='color:black;letter-spacing:.15pt'>musculoskeletal pain,<sup>a</sup>
  arthralgia</span></p>
  </td>
 </tr>
 <tr style='height:13.45pt'>
  <td width=138 valign=top style='width:103.7pt;border:solid windowtext 1.0pt;
  border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
  style='color:black'>Uncommon</span></p>
  </td>
  <td width=485 valign=top style='width:364.1pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
  style='color:black;letter-spacing:.15pt'>polymyalgia rheumatica</span></p>
  </td>
 </tr>
 <tr style='height:14.15pt'>
  <td width=624 colspan=2 valign=top style='width:467.8pt;border:solid windowtext 1.0pt;
  border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:14.15pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><b><span lang=EN-GB
  style='color:black'>Renal and urinary disorders</span></b></p>
  </td>
 </tr>
 <tr style='height:13.45pt'>
  <td width=138 valign=top style='width:103.7pt;border:solid windowtext 1.0pt;
  border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
  style='color:black'>Uncommon</span></p>
  </td>
  <td width=485 valign=top style='width:364.1pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
  style='color:black;letter-spacing:.15pt'>tubulointerstitial nephritis, renal
  failure</span></p>
  </td>
 </tr>
 <tr style='height:14.15pt'>
  <td width=624 colspan=2 valign=top style='width:467.8pt;border:solid windowtext 1.0pt;
  border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:14.15pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><b><span lang=EN-GB
  style='color:black'>General disorders and administration site conditions</span></b></p>
  </td>
 </tr>
 <tr style='height:13.45pt'>
  <td width=138 valign=top style='width:103.7pt;border:solid windowtext 1.0pt;
  border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
  style='color:black'>Very common</span></p>
  </td>
  <td width=485 valign=top style='width:364.1pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
  style='color:black;letter-spacing:.15pt'>fatigue</span></p>
  </td>
 </tr>
 <tr style='height:13.45pt'>
  <td width=138 valign=top style='width:103.7pt;border:solid windowtext 1.0pt;
  border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
  style='color:black'>Common</span></p>
  </td>
  <td width=485 valign=top style='width:364.1pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
  style='color:black;letter-spacing:.15pt'>pyrexia, oedema</span></p>
  </td>
 </tr>
 <tr style='height:14.15pt'>
  <td width=624 colspan=2 valign=top style='width:467.8pt;border:solid windowtext 1.0pt;
  border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:14.15pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><b><span lang=EN-GB
  style='color:black'>Investigations</span></b></p>
  </td>
 </tr>
 <tr style='height:13.45pt'>
  <td width=138 valign=top style='width:103.7pt;border:solid windowtext 1.0pt;
  border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
  style='color:black'>Very common</span></p>
  </td>
  <td width=485 valign=top style='width:364.1pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
  style='color:black'>increased AST,<sup>b</sup>increased ALT,<sup>b</sup>
  increased alkaline phosphatase,<sup>b </sup></span><span lang=EN-GB
  style='color:black;letter-spacing:.15pt'>increased creatinine,</span><sup><span
  lang=EN-GB style='color:black'>b</span></sup><span lang=EN-GB
  style='color:black;letter-spacing:.15pt'> </span><span lang=EN-GB
  style='color:black'>decreased lymphocytes,<sup>b</sup> decreased platelet
  count,<sup>b</sup> decreased haemoglobin,<sup>b </sup>hypercalcaemia,<sup>b</sup>
  hypocalcaemia,<sup>b</sup> hyperkalaemia,<sup>b</sup> hypokalaemia,<sup>b</sup>
  hypomagnesaemia,<sup>b</sup> hyponatraemia<sup>b</sup></span></p>
  </td>
 </tr>
 <tr style='height:13.45pt'>
  <td width=138 valign=top style='width:103.7pt;border:solid windowtext 1.0pt;
  border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
  style='color:black'>Common</span></p>
  </td>
  <td width=485 valign=top style='width:364.1pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
  style='color:black;letter-spacing:.15pt'>increased total bilirubin,</span><sup><span
  lang=EN-GB style='color:black'>b</span></sup><span lang=EN-GB
  style='color:black;letter-spacing:.15pt'> </span><span lang=EN-GB
  style='color:black'>decreased absolute neutrophil count,<sup>b </sup>hypermagnesaemia,<sup>b,
  </sup>hypernatraemia<sup>b</sup></span></p>
  </td>
 </tr>
 <tr style='height:13.45pt'>
  <td width=138 valign=top style='width:103.7pt;border:solid windowtext 1.0pt;
  border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
  style='color:black'>Uncommon</span></p>
  </td>
  <td width=485 valign=top style='width:364.1pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
  style='color:black;letter-spacing:.15pt'>Increased lipase, increased amylase</span></p>
  </td>
 </tr>
</table>

<p class=EMEABodyText style='margin-left:28.35pt;text-indent:-28.35pt;
page-break-after:avoid'><span class=EMEASuperscript><span lang=EN-GB>a</span></span><span
lang=EN-GB style='font-size:10.0pt'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Musculoskeletal
pain is a composite term which includes back pain, bone pain, musculoskeletal
chest pain, musculoskeletal discomfort, myalgia, neck pain, pain in extremity,
pain in jaw, spinal pain.</span></p>

<p class=EMEABodyText style='margin-left:28.35pt;text-indent:-28.35pt;
page-break-after:avoid'><span class=EMEASuperscript><span lang=EN-GB>b</span></span><span
lang=EN-GB style='font-size:10.0pt'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Frequencies
reflect the proportion of patients who experienced a worsening from baseline in
laboratory measurements. See &#8220;Description of selected adverse reactions;
laboratory abnormalities&#8221; below.</span></p>

<p class=EMEABodyText><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB>Description
of selected adverse reactions</span></u></p>

<p class=EMEABodyText><span lang=EN-GB>Data for the following immune&#8209;related
adverse reactions are based on patients who received
nivolumab&nbsp;3&nbsp;mg/kg in two NSCLC studies (CA209017 and CA209063, see
section&nbsp;5.1). The management guidelines for these adverse reactions are
described in section&nbsp;4.4.</span></p>

<p class=EMEABodyText><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=EMEABodyText style='page-break-after:avoid'><i><u><span lang=EN-GB>Immune-related
pneumonitis</span></u></i></p>

<p class=EMEABodyText><span lang=EN-GB>In CA209017 and CA209063, the incidence
of pneumonitis, including interstitial lung disease, was 5.2%&nbsp;(13/248).
Grade 2&nbsp;and Grade&nbsp;3 cases were reported in 2.8% (7/248) and 1.6% (4/248)
of patients, respectively. No Grade&nbsp;4 or&nbsp;5 cases reported in these
studies. In the phase 1 study MDX1106-03, pneumonitis, including a Grade 4 case
in 1 patient, was reported in 3/37 patients (8.1%) with NSCLC receiving
nivolumab </span><span lang=EN-GB>3&nbsp;mg/kg.</span></p>

<p class=EMEABodyText><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=EMEABodyText><span lang=EN-GB>Median time to onset was 11.6&nbsp;weeks
(range: 2.6-85.1). Eleven patients received high-dose corticosteroids (at least
40&nbsp;mg prednisone equivalents) at a median initial dose of 1.1&nbsp;mg/kg
(range:&nbsp;0.5-4.0) for a median total duration of 4.3 weeks (range:&nbsp;0.6-13.1).
Eight patients, including the 4 patients with a Grade 3 case, required
permanent discontinuation of nivolumab due to pneumonitis. Resolution occurred
in all 13 patients with a median time to resolution of 3.9 weeks (range: 0.6-13.4).</span></p>

<p class=EMEABodyText><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=EMEABodyText style='page-break-after:avoid'><i><u><span lang=EN-GB>Immune&#8209;related
colitis</span></u></i></p>

<p class=EMEABodyText><span lang=EN-GB>In CA209017 and CA209063, the incidence
of diarrhoea or colitis was&nbsp;9.3% (23/248). Grade&nbsp;2 and Grade&nbsp;3&nbsp;cases
were reported in&nbsp;2% (5/248) and 1.6% (4/248)&nbsp;of patients,
respectively. No Grade&nbsp;4&nbsp;or&nbsp;5&nbsp;cases were reported in these
studies.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Median time to onset was&nbsp;5.6&nbsp;weeks
(range:&nbsp;0.1&#8209;91.0). Three patients, </span><span lang=EN-GB>including&nbsp;2&nbsp;patients
with a Grade&nbsp;3&nbsp;case,</span><span lang=EN-GB> received high&#8209;dose
corticosteroids (at least&nbsp;40&nbsp;mg prednisone equivalents) at a median
initial dose of 0.6&nbsp;mg/kg (range: 0.4-1.3) for a median duration of 2.0&nbsp;weeks
(range: 1.4-14.1). One patient required permanent discontinuation of nivolumab
due to Grade 3 diarrhoea. Resolution occurred in 19&nbsp;patients (83%) with a
median time to resolution of 2.0&nbsp;weeks (range:&nbsp;0.1&#8209;31.0).</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><i><u><span lang=EN-GB>Immune&#8209;related
hepatitis</span></u></i></p>

<p class=EMEABodyText><span lang=EN-GB>In CA209017 and CA209063, the incidence
of liver function test abnormalities was 1.2% (3/248). Grade&nbsp;2 cases were
reported in 0.4% (1/248) of patients. No Grade&nbsp;3-5 cases were reported in
these studies. </span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Median time to onset was 25.1 weeks
(range: 4.1-31.1). None of these patients received high-dose corticosteroids. One
patient required permanent discontinuation of nivolumab due to Grade 2 increases
in transaminases. Resolution occurred in 2&nbsp;patients (67%) with a median
time to resolution of 4.1&nbsp;weeks (range:&nbsp;2.9&#8209;22.3<sup>+</sup>); <span
class=EMEASuperscript>+</span> denotes a censored observation.</span></p>

<p class=EMEABodyText><i><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></i></p>

<p class=EMEABodyText style='page-break-after:avoid'><i><u><span lang=EN-GB>Immune&#8209;related
nephritis and renal dysfunction</span></u></i></p>

<p class=EMEABodyText><span lang=EN-GB>In CA209017 and CA209063, the incidence
of nephritis or renal dysfunction was 3.2%&nbsp;(8/248). Grade&nbsp;2 and Grade&nbsp;3
cases were reported in 1.2% (3/248) and 0.4% (1/248) of patients, respectively.
No Grade&nbsp;4&nbsp;or&nbsp;5 nephritis or renal dysfunction was reported in
these studies.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Median time to onset was&nbsp;10.5 weeks
(range:&nbsp;2.1&#8209;27.0). Two patients, including the one patient with a Grade&nbsp;3&nbsp;case
(tubulointerstitial nephritis), received high&#8209;dose corticosteroids (at
least 40&nbsp;mg prednisone equivalents) at a median initial dose of 0.8&nbsp;mg/kg
(range: 0.5-1.2) for a median duration of 5.3&nbsp;weeks (range: 0.9-9.7).
Resolution occurred in 5 patients (71%), including the Grade&nbsp;3 case, with
a median time to resolution of 5.9&nbsp;weeks (range: 0.7- 37.6<sup>+</sup>); <span
class=EMEASuperscript>+</span> denotes a censored observation.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><i><u><span lang=EN-GB>Immune-related
endocrinopathies</span></u></i></p>

<p class=EMEABodyText><span lang=EN-GB>In CA209017 and CA209063, the incidence
of thyroid disorders, including hypothyroidism or thyroiditis, was&nbsp;4.4%&nbsp;(11/248).
Grade&nbsp;2 cases were reported in 3.6% (9/248) of patients. No Grade 3&#8209;5
thyroid disorders were reported. The incidence of adrenal insufficiency was 0.4%
(1/248; Grade&nbsp;3). There were no reports of hypophysitis, diabetes
mellitus, or diabetic ketoacidosis in these studies.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Median time to onset of these
endocrinopathies was&nbsp;17.8&nbsp;weeks (range: 6.1&#8209;33.1). Three
patients, including the one patient with Grade&nbsp;3 adrenal insufficiency,
received high&#8209;dose corticosteroids (at least 40&nbsp;mg prednisone
equivalents) at a median initial dose of 1.1&nbsp;mg/kg (range: 0.5-1.3) for 2.7&nbsp;weeks
(range: 0.6-4.6). The Grade&nbsp;3 case required permanent discontinuation of
nivolumab. Resolution occurred in 6&nbsp;patients (50%) with a median time to
resolution of 20.6&nbsp;weeks (0.4-47.6<sup>+</sup>); <span
class=EMEASuperscript>+</span> denotes a censored observation. </span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><i><u><span lang=EN-GB>Immune-related rash </span></u></i></p>

<p class=EMEABodyText><span lang=EN-GB>In CA209017 and CA209063, the incidence
of rash was 12.1%&nbsp;(30/248). Grade&nbsp;2 and Grade&nbsp;3 cases were
reported in 1.6% (4/248) and 0.8% (2/248) of patients, respectively. No
Grade&nbsp;4&nbsp;or&nbsp;5 rash was reported in these studies.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Median time to onset was 8.1&nbsp;weeks
(range:&nbsp;0.3&#8209;51.9). None of these patients received high-dose
corticosteroids. Two patients (1 with Grade&nbsp;2 rash and 1 with Grade&nbsp;3
rash) required permanent discontinuation of nivolumab. Resolution occurred in
24&nbsp;patients (83%), including the 2&nbsp;patients with a Grade&nbsp;3 case,
with a median time to resolution of 5.7&nbsp;weeks (range: 0.1- 46.9<sup>+</sup>);
<span class=EMEASuperscript>+</span> denotes a censored observation.</span></p>

<p class=EMEABodyText><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=EMEABodyText style='page-break-after:avoid'><i><u><span lang=EN-GB>Infusion
reactions</span></u></i></p>

<p class=EMEABodyText><span lang=EN-GB>In CA209017 and CA209063, the incidence
of hypersensitivity/infusion reactions was 1.6% (4/248). Grade&nbsp;3
anaphylactic reaction and Grade&nbsp;4 hypersensitivity were each reported in 1&nbsp;patient;
both of these cases led to discontinuation and resolved with treatment.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><i><u><span lang=EN-GB>Laboratory
abnormalities</span></u></i></p>

<p class=BMSBodyText align=left style='margin-bottom:0in;text-align:left;
line-height:normal'><span lang=EN-GB style='font-size:11.0pt;color:windowtext'>In
CA209017 and CA209063, the proportion of patients who experienced a shift from
baseline to a Grade&nbsp;3&nbsp;or&nbsp;4 laboratory abnormality was as
follows: 13.2% for decreased lymphocytes, 9% for hyponatraemia, 2.9% for
hypercalcaemia and hyperkalaemia, 2.5% for decreased haemoglobin (all
Grade&nbsp;3), 2.0% for hypokalaemia, 1.6% for decreased neutrophil count, 1.3%
for hypomagnesaemia, 1.2% for hypocalcaemia, 0.8% for increased total bilirubin,
and 0.4% for increased AST, decreased platelet, hypermagnesaemia, and
hypernatraemia. There was no worsening to Grade&nbsp;3&nbsp;or&nbsp;4 in increased
ALT, increased alkaline phosphatase, and increased creatinine</span><span
lang=EN-GB style='font-size:10.0pt;color:windowtext'>.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>In study CA209017, hypercalcaemia was more
frequently reported in the nivolumab group (31/130, 24%) than in the docetaxel
group (9/124, 7%). The exact cause is not known. Although hyperparathyroidism
was not reported in CA209017, immune-related hyperparathyroidism might be
considered especially if associated with hypophosphataemia (reported in
6&nbsp;hypercalcemic patients in this study).</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText style='page-break-after:avoid'><i><u><span lang=EN-GB>Immunogenicity</span></u></i></p>

<p class=EMEABodyText><span lang=EN-GB>As with all therapeutic proteins, there
is a potential for an immune response to nivolumab. Of the 497&nbsp;patients
who were treated with nivolumab 3&nbsp;mg/kg every 2&nbsp;weeks and evaluable
for the presence of anti&#8209;product&#8209;antibodies, 51&nbsp;(10.3%)
patients tested positive for treatment-emergent anti-product antibodies by an
electrochemiluminescent (ECL) assay. Only 4&nbsp;(0.8%)&nbsp;patients were
persistent positive. Neutralising antibodies were detected in only 5&nbsp;(1.0%
of the total) of the positive anti&#8209;product&#8209;antibody patients. There
was no evidence of altered pharmacokinetic or toxicity profile associated with
anti&#8209;product&#8209;antibody development.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB>Reporting
of suspected adverse reactions</span></u></p>

<p class=EMEABodyText><span lang=EN-GB>Reporting suspected adverse reactions
after authorisation of the medicinal product is important. It allows continued
monitoring of the benefit/risk balance of the medicinal product. Healthcare
professionals are asked to report any suspected adverse reactions via <span
style='background:silver'>the national reporting system listed in </span></span><span
lang=EN-GB style='background:silver'><a
href="http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc">Appendix
V</a></span><span lang=EN-GB style='background:silver'>.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading2><span lang=EN-GB>4.9&nbsp;&nbsp;&nbsp;&nbsp; Overdose</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>No cases of overdose have been reported
in clinical trials. In case of overdose, patients should be closely monitored
for signs or symptoms of adverse reactions, and appropriate symptomatic
treatment instituted immediately.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading1><span lang=EN-GB>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PHARMACOLOGICAL
PROPERTIES</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading2><span lang=EN-GB>5.1 &nbsp;&nbsp;&nbsp; Pharmacodynamic
properties</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Pharmacotherapeutic group: Antineoplastic
agents, monoclonal antibodies. ATC code: </span><span lang=EN-GB>L01XC17.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB>Mechanism
of action</span></u></p>

<p class=EMEABodyText><span lang=EN-GB>Nivolumab is a human immunoglobulin G4
(IgG4) monoclonal antibody (HuMAb), which binds to the programmed death&#8209;1
(PD&#8209;1) receptor and blocks its interaction with PD&#8209;L1 and PD&#8209;L2.
The PD&#8209;1 receptor is a negative regulator of T&#8209;cell activity that
has been shown to be involved in the control of T&#8209;cell immune responses.
Engagement of PD&#8209;1 with the ligands PD&#8209;L1 and PD&#8209;L2, which are
expressed in antigen presenting cells and may be expressed by tumours or other
cells in the tumour microenvironment, results in inhibition of T&#8209;cell
proliferation and cytokine secretion. Nivolumab potentiates T&#8209;cell
responses, including anti-tumour responses, through blockade of PD&#8209;1
binding to PD&#8209;L1 and PD&#8209;L2 ligands. In syngeneic mouse models,
blocking PD&#8209;1 activity resulted in decreased tumour growth.</span></p>

<p class=EMEABodyText><u><span style='text-decoration:none'>&nbsp;</span></u></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB>Clinical
efficacy and safety</span></u></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=EMEABodyText style='page-break-after:avoid'><i><u><span lang=EN-GB>Randomised
phase&nbsp;3 study vs. docetaxel (CA209017)</span></u></i></p>

<p class=EMEABodyText><span lang=EN-GB>The safety and efficacy of
nivolumab&nbsp;3&nbsp;mg/kg as a single agent for the treatment of advanced or
metastatic squamous NSCLC were evaluated in a phase&nbsp;3, randomised,
open-label study (CA209017). The study included patients (18&nbsp;years or
older) who have experienced disease progression during or after one prior
platinum doublet-based chemotherapy regimen and an Eastern Cooperative Oncology
Group (ECOG) performance status score of 0 or 1. Patients were enrolled
regardless of their PD-L1 status. Patients with active autoimmune disease,
symptomatic interstitial lung disease, or untreated brain metastasis were
excluded from the study. Patients with treated brain metastases were eligible
if neurologically returned to baseline at least 2&nbsp;weeks prior to
enrolment, and either off corticosteroids, or on a stable or decreasing dose of
&lt;10 mg daily prednisone equivalents.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>A total of 272 patients were randomised
to receive either nivolumab 3&nbsp;mg/kg (N&nbsp;=&nbsp;135) administered
intravenously over&nbsp;60&nbsp;minutes every&nbsp;2&nbsp;weeks or docetaxel (n&nbsp;=&nbsp;137)
75&nbsp;mg/m<sup>2</sup> every 3&nbsp;weeks. Treatment was continued as long as
clinical benefit was observed or until treatment was no longer tolerated. </span><span
lang=EN-GB>T</span><span lang=EN-GB>umour assessments,</span><span lang=EN-GB> according
to the Response Evaluation Criteria in Solid Tumours (RECIST), version 1.1, </span><span
lang=EN-GB>were conducted&nbsp;9 weeks after randomisation and continued every&nbsp;6&nbsp;weeks
thereafter. The primary efficacy outcome measure was overall survival (OS). Key
secondary efficacy outcome measures were investigator-assessed objective
response rate (ORR) and progression-free survival (PFS). In addition, symptom
improvement and overall health status were assessed using the Lung Cancer
Symptom Score (LCSS) average symptom burden index and the EQ-5D Visual Analogue
Scale (EQ-VAS), respectively. </span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Baseline characteristics were generally balanced
between the two groups. The median age was&nbsp;63&nbsp;years (range:&nbsp;39&#8209;85)
with 44% </span><span lang=EN-GB style='font-family:Symbol'>&sup3;</span><span
lang=EN-GB>65&nbsp;years of age and 11% </span><span lang=EN-GB
style='font-family:Symbol'>&sup3;</span><span lang=EN-GB>75&nbsp;years of age. The
majority of patients were white (93%) and male (76%). Thirty-one percent had
progressive disease reported as the best response to their most recent prior
regimen and 45% received nivolumab within 3&nbsp;months of completing their
most recent prior regimen. Baseline ECOG performance status score was 0&nbsp;(24%)
or 1&nbsp;(76%). </span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>The Kaplan-Meier curves for OS are shown
in Figure&nbsp;1.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><b>Figure 1:&nbsp;&nbsp;&nbsp; Kaplan-Meier
curves of OS (CA209017) </b></p>

<p class=EMEABodyText style='page-break-after:avoid'><b>&nbsp;</b></p>

<p class=EMEABodyText align=center style='text-align:center;page-break-after:
avoid'><span style='position:absolute;z-index:251657728;left:0px;margin-left:
1px;margin-top:17px;width:39px;height:336px'><img width=39 height=336
src="Nivolumab%20BMS-3840%20-%20EN%20PI%20clea_files/image002.gif"
alt="Text Box: Probability of Survival"></span><span lang=EN-GB><img border=0
width=527 height=377 id="Picture 4"
src="Nivolumab%20BMS-3840%20-%20EN%20PI%20clea_files/image003.jpg"></span></p>

<p class=EMEABodyText align=center style='text-align:center;page-break-after:
avoid'><span lang=EN-GB>Overall Survival (Months)</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Number of
Subjects at Risk</span></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=567
 style='margin-left:5.4pt;border-collapse:collapse'>
 <tr>
  <td width=567 colspan=9 valign=top style='width:425.25pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Nivolumab
  3 mg/kg</span></p>
  </td>
 </tr>
 <tr>
  <td width=85 valign=top style='width:63.8pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=right style='text-align:right;page-break-after:
  avoid'><span lang=EN-GB>135</span></p>
  </td>
  <td width=59 valign=top style='width:44.1pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=right style='text-align:right;page-break-after:
  avoid'><span lang=EN-GB>113</span></p>
  </td>
  <td width=59 valign=top style='width:44.1pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=right style='text-align:right;page-break-after:
  avoid'><span lang=EN-GB>86</span></p>
  </td>
  <td width=62 valign=top style='width:46.45pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=right style='text-align:right;page-break-after:
  avoid'><span lang=EN-GB>69</span></p>
  </td>
  <td width=57 valign=top style='width:42.55pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=right style='text-align:right;page-break-after:
  avoid'><span lang=EN-GB>52</span></p>
  </td>
  <td width=66 valign=top style='width:49.6pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=right style='text-align:right;page-break-after:
  avoid'><span lang=EN-GB>31</span></p>
  </td>
  <td width=57 valign=top style='width:42.55pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=right style='text-align:right;page-break-after:
  avoid'><span lang=EN-GB>15</span></p>
  </td>
  <td width=57 valign=top style='width:42.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=right style='text-align:right;page-break-after:
  avoid'><span lang=EN-GB>7</span></p>
  </td>
  <td width=66 valign=top style='width:49.6pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=right style='text-align:right;page-break-after:
  avoid'><span lang=EN-GB>0</span></p>
  </td>
 </tr>
 <tr>
  <td width=567 colspan=9 valign=top style='width:425.25pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Docetaxel</span></p>
  </td>
 </tr>
 <tr>
  <td width=85 valign=top style='width:63.8pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=right style='text-align:right;page-break-after:
  avoid'><span lang=EN-GB>137</span></p>
  </td>
  <td width=59 valign=top style='width:44.1pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=right style='text-align:right;page-break-after:
  avoid'><span lang=EN-GB>103</span></p>
  </td>
  <td width=59 valign=top style='width:44.1pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=right style='text-align:right;page-break-after:
  avoid'><span lang=EN-GB>68</span></p>
  </td>
  <td width=62 valign=top style='width:46.45pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=right style='text-align:right;page-break-after:
  avoid'><span lang=EN-GB>45</span></p>
  </td>
  <td width=57 valign=top style='width:42.55pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=right style='text-align:right;page-break-after:
  avoid'><span lang=EN-GB>30</span></p>
  </td>
  <td width=66 valign=top style='width:49.6pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=right style='text-align:right;page-break-after:
  avoid'><span lang=EN-GB>14</span></p>
  </td>
  <td width=57 valign=top style='width:42.55pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=right style='text-align:right;page-break-after:
  avoid'><span lang=EN-GB>7</span></p>
  </td>
  <td width=57 valign=top style='width:42.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=right style='text-align:right;page-break-after:
  avoid'><span lang=EN-GB>2</span></p>
  </td>
  <td width=66 valign=top style='width:49.6pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=right style='text-align:right;page-break-after:
  avoid'><span lang=EN-GB>0</span></p>
  </td>
 </tr>
</table>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB><img
border=0 width=49 height=21
src="Nivolumab%20BMS-3840%20-%20EN%20PI%20clea_files/image004.jpg">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Nivolumab
3 mg/kg (events : 86/135), median and 95% CI : 9.23 (7.33, 13.27)</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB><img
border=0 width=45 height=21
src="Nivolumab%20BMS-3840%20-%20EN%20PI%20clea_files/image005.jpg">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Docetaxel
(events : 113/137), median and 95% CI : 6.01 (5.13, 7.33)</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>The observed OS benefit was consistently
demonstrated across subgroups of patients. Survival benefit was observed
regardless of whether patients had tumours that were designated PD-L1 negative
or PD-L1 positive (tumour membrane expression cut off of 1%, 5% or 10%).
However, the role of this biomarker (PD-L1 expression) has not been fully
elucidated.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Study CA209017 included a limited number
of patients &#8805; 75&nbsp;years (11&nbsp;in the nivolumab group and 18&nbsp;in
the docetaxel group). Nivolumab showed numerically less effect on OS (HR&nbsp;1.85;
95% CI: 0.76, 4.51), PFS (HR=1.76; 95%-CI: 0.77, 4.05 ) and ORR (9.1% vs
16.7%). Because of the small sample size, no definitive conclusions can be
drawn from these data.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Efficacy results are shown in Table&nbsp;3.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><b><span lang=EN-GB>Table
3</span></b><span lang=EN-GB>:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <b>Efficacy
results (CA209017)</b></span></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0
 style='border-collapse:collapse'>
 <tr>
  <td width=202 valign=top style='width:151.55pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
  <td width=225 colspan=2 valign=top style='width:168.8pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>nivolumab<br>
  (n&nbsp;=&nbsp;135)</span></b></p>
  </td>
  <td width=192 colspan=2 valign=top style='width:2.0in;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>docetaxel<br>
  (n&nbsp;=&nbsp;137)</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=202 valign=top style='width:151.55pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:10.0pt'>Overall survival </span></b></p>
  </td>
  <td width=106 valign=top style='width:79.5pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=right style='text-align:right;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width=119 valign=top style='width:89.3pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width=81 valign=top style='width:60.5pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=right style='text-align:right;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width=111 valign=top style='width:83.5pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=202 valign=top style='width:151.55pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;&nbsp;&nbsp; Events</span></p>
  </td>
  <td width=225 colspan=2 style='width:168.8pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>86 (63.7)</span></p>
  </td>
  <td width=192 colspan=2 style='width:2.0in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>113 (82.5)</span></p>
  </td>
 </tr>
 <tr>
  <td width=202 valign=top style='width:151.55pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>Hazard ratio </span></p>
  </td>
  <td width=417 colspan=4 valign=top style='width:312.8pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>0.59</span></p>
  </td>
 </tr>
 <tr>
  <td width=202 valign=top style='width:151.55pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt;color:black'>96.85% CI</span></p>
  </td>
  <td width=417 colspan=4 valign=top style='width:312.8pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>(0.43, 0.81)</span></p>
  </td>
 </tr>
 <tr>
  <td width=202 valign=top style='width:151.55pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>p&#8209;value</span></p>
  </td>
  <td width=417 colspan=4 valign=top style='width:312.8pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>0.0002</span></p>
  </td>
 </tr>
 <tr>
  <td width=202 valign=top style='width:151.55pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width=106 valign=top style='width:79.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=right style='text-align:right;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width=119 valign=top style='width:89.3pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width=81 valign=top style='width:60.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=right style='text-align:right;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width=111 valign=top style='width:83.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=202 valign=top style='width:151.55pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;&nbsp;&nbsp; Median (95% CI) months</span></p>
  </td>
  <td width=225 colspan=2 style='width:168.8pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText>9.23 (7.33, 13.27)</p>
  </td>
  <td width=192 colspan=2 style='width:2.0in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText>6.01 (5.13, 7.33)</p>
  </td>
 </tr>
 <tr>
  <td width=202 valign=top style='width:151.55pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;&nbsp;&nbsp; Rate (95% CI) at 12&nbsp;months</span></p>
  </td>
  <td width=225 colspan=2 valign=top style='width:168.8pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>42.1 (33.7, 50.3)</span></p>
  </td>
  <td width=192 colspan=2 valign=top style='width:2.0in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>23.7 (16.9, 31.1)</span></p>
  </td>
 </tr>
 <tr>
  <td width=202 valign=top style='width:151.55pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:10.0pt'>Confirmed objective response </span></b></p>
  </td>
  <td width=106 valign=top style='width:79.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=right style='text-align:right;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>27</span></p>
  </td>
  <td width=119 valign=top style='width:89.3pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:10.0pt'>(20.0%)</span></p>
  </td>
  <td width=81 valign=top style='width:60.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=right style='text-align:right;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>12</span></p>
  </td>
  <td width=111 valign=top style='width:83.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:10.0pt'>(8.8%)</span></p>
  </td>
 </tr>
 <tr>
  <td width=202 valign=top style='width:151.55pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>(95% CI)</span></p>
  </td>
  <td width=225 colspan=2 valign=top style='width:168.8pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>(13.6, 27.7)</span></p>
  </td>
  <td width=192 colspan=2 valign=top style='width:2.0in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>(4.6, 14.8)</span></p>
  </td>
 </tr>
 <tr>
  <td width=202 valign=top style='width:151.55pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>Odds ratio (95% CI)</span></p>
  </td>
  <td width=417 colspan=4 valign=top style='width:312.8pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>2.64 (1.27, 5.49)</span></p>
  </td>
 </tr>
 <tr>
  <td width=202 valign=top style='width:151.55pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>p&#8209;value</span></p>
  </td>
  <td width=417 colspan=4 valign=top style='width:312.8pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>0.0083</span></p>
  </td>
 </tr>
 <tr>
  <td width=202 valign=top style='width:151.55pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width=106 valign=top style='width:79.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=right style='text-align:right;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width=119 valign=top style='width:89.3pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width=81 valign=top style='width:60.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=right style='text-align:right;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width=111 valign=top style='width:83.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=202 valign=top style='width:151.55pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;&nbsp;&nbsp; Complete response (CR)</span></p>
  </td>
  <td width=106 valign=top style='width:79.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=right style='text-align:right;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>1</span></p>
  </td>
  <td width=119 valign=top style='width:89.3pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:10.0pt'>(0.7%)</span></p>
  </td>
  <td width=81 valign=top style='width:60.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=right style='text-align:right;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>0 </span></p>
  </td>
  <td width=111 valign=top style='width:83.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=202 valign=top style='width:151.55pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;&nbsp;&nbsp; Partial response (PR)</span></p>
  </td>
  <td width=106 valign=top style='width:79.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=right style='text-align:right;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>26</span></p>
  </td>
  <td width=119 valign=top style='width:89.3pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:10.0pt'>(19.3%)</span></p>
  </td>
  <td width=81 valign=top style='width:60.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=right style='text-align:right;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>12 </span></p>
  </td>
  <td width=111 valign=top style='width:83.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:10.0pt'>(8.8%)</span></p>
  </td>
 </tr>
 <tr>
  <td width=202 valign=top style='width:151.55pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;&nbsp;&nbsp; Stable disease (SD)</span></p>
  </td>
  <td width=106 valign=top style='width:79.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=right style='text-align:right;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>39</span></p>
  </td>
  <td width=119 valign=top style='width:89.3pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:10.0pt'>(28.9%)</span></p>
  </td>
  <td width=81 valign=top style='width:60.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=right style='text-align:right;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>47 </span></p>
  </td>
  <td width=111 valign=top style='width:83.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:10.0pt'>(34.3%)</span></p>
  </td>
 </tr>
 <tr>
  <td width=202 valign=top style='width:151.55pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width=106 valign=top style='width:79.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=right style='text-align:right;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width=119 valign=top style='width:89.3pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width=81 valign=top style='width:60.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=right style='text-align:right;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width=111 valign=top style='width:83.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=202 valign=top style='width:151.55pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:10.0pt'>Median duration of response </span></b></p>
  </td>
  <td width=225 colspan=2 valign=top style='width:168.8pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width=81 valign=top style='width:60.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=right style='text-align:right;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width=111 valign=top style='width:83.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=202 valign=top style='width:151.55pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;&nbsp;&nbsp; Months (range)</span></p>
  </td>
  <td width=106 valign=top style='width:79.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=right style='text-align:right;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>Not reached</span></p>
  </td>
  <td width=119 valign=top style='width:89.3pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:10.0pt'>(2.9 - 20.5<sup>+</sup>)</span></p>
  </td>
  <td width=81 valign=top style='width:60.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=right style='text-align:right;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>8.4</span></p>
  </td>
  <td width=111 valign=top style='width:83.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:10.0pt'>(1.4<sup>+</sup> - 15.2<sup>+</sup>)</span></p>
  </td>
 </tr>
 <tr>
  <td width=202 valign=top style='width:151.55pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width=106 valign=top style='width:79.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=right style='text-align:right;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width=119 valign=top style='width:89.3pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width=81 valign=top style='width:60.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=right style='text-align:right;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width=111 valign=top style='width:83.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=202 valign=top style='width:151.55pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:10.0pt'>Median time to response</span></b></p>
  </td>
  <td width=106 valign=top style='width:79.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=right style='text-align:right;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width=119 valign=top style='width:89.3pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width=81 valign=top style='width:60.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=right style='text-align:right;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width=111 valign=top style='width:83.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='height:13.05pt'>
  <td width=202 valign=top style='width:151.55pt;padding:0in 5.4pt 0in 5.4pt;
  height:13.05pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;&nbsp;&nbsp; Months (range)</span></p>
  </td>
  <td width=106 valign=top style='width:79.5pt;padding:0in 5.4pt 0in 5.4pt;
  height:13.05pt'>
  <p class=MsoNormal align=right style='text-align:right;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>2.2</span></p>
  </td>
  <td width=119 valign=top style='width:89.3pt;padding:0in 5.4pt 0in 5.4pt;
  height:13.05pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:10.0pt'>(1.6 - 11.8)</span></p>
  </td>
  <td width=81 valign=top style='width:60.5pt;padding:0in 5.4pt 0in 5.4pt;
  height:13.05pt'>
  <p class=MsoNormal align=right style='text-align:right;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>2.1</span></p>
  </td>
  <td width=111 valign=top style='width:83.5pt;padding:0in 5.4pt 0in 5.4pt;
  height:13.05pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:10.0pt'>(1.8 - 9.5)</span></p>
  </td>
 </tr>
 <tr>
  <td width=202 valign=top style='width:151.55pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:10.0pt'>Progression-free survival</span></b></p>
  </td>
  <td width=106 valign=top style='width:79.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=right style='text-align:right;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width=119 valign=top style='width:89.3pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width=81 valign=top style='width:60.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=right style='text-align:right;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width=111 valign=top style='width:83.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=202 valign=top style='width:151.55pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;&nbsp;&nbsp; Events</span></p>
  </td>
  <td width=225 colspan=2 style='width:168.8pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>105 (77.8)</span></p>
  </td>
  <td width=192 colspan=2 style='width:2.0in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>122 (89.1)</span></p>
  </td>
 </tr>
 <tr>
  <td width=202 valign=top style='width:151.55pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>Hazard ratio </span></p>
  </td>
  <td width=417 colspan=4 valign=top style='width:312.8pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>0.62 </span></p>
  </td>
 </tr>
 <tr>
  <td width=202 valign=top style='width:151.55pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt;color:black'>95% CI</span></p>
  </td>
  <td width=417 colspan=4 valign=top style='width:312.8pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>(0.47, 0.81)</span></p>
  </td>
 </tr>
 <tr>
  <td width=202 valign=top style='width:151.55pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>p&#8209;value</span></p>
  </td>
  <td width=417 colspan=4 valign=top style='width:312.8pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>&lt; 0.0004</span></p>
  </td>
 </tr>
 <tr>
  <td width=202 valign=top style='width:151.55pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width=106 valign=top style='width:79.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=right style='text-align:right;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width=119 valign=top style='width:89.3pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width=81 valign=top style='width:60.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=right style='text-align:right;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width=111 valign=top style='width:83.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=202 valign=top style='width:151.55pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;&nbsp;&nbsp; Median (95% CI) (months)</span></p>
  </td>
  <td width=225 colspan=2 valign=top style='width:168.8pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText style='page-break-after:avoid'>3.48 (2.14, 4.86)</p>
  </td>
  <td width=192 colspan=2 valign=top style='width:2.0in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText style='page-break-after:avoid'>2.83 (2.10, 3.52)</p>
  </td>
 </tr>
 <tr>
  <td width=202 valign=top style='width:151.55pt;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;&nbsp;&nbsp; Rate (95% CI) at 12&nbsp;months</span></p>
  </td>
  <td width=225 colspan=2 valign=top style='width:168.8pt;border:none;
  border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText>20.8 (14.0, 28.4)</p>
  </td>
  <td width=192 colspan=2 valign=top style='width:2.0in;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText style='margin-top:0in'>6.4 (2.9, 11.8)</p>
  </td>
 </tr>
</table>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>The rate of disease-related symptom
improvement, as measured by LCSS, was similar between the nivolumab group
(18.5%) and the docetaxel group (21.2%). The average EQ-VAS increased over time
for both treatment groups, indicating better overall health status for patients
remaining on treatment.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><i><u><span lang=EN-GB>Single-arm
phase&nbsp;2&nbsp;study (CA209063)</span></u></i></p>

<p class=EMEABodyText><span lang=EN-GB>Study CA209063 was a single-arm, open-label
study conducted in 117&nbsp;patients with locally advanced or metastatic
squamous-NSCLC after two or more lines of therapy; otherwise similar inclusion
criteria as study CA209017 were applied. Nivolumab 3&nbsp;mg/kg showed an
overall response rate of 14.5% (95% CI: 8.7-22.2%), a median OS of
8.21&nbsp;months (95% CI: 6.05-10.9&nbsp;months ), and a median PFS of 1.87&nbsp;months
(95% CI 1.77-3.15&nbsp;months. The PFS was measured by RECIST version 1.1. The
estimated 1-year survival rate was 41%.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><u>Safety and efficacy in
elderly patients</u></p>

<p class=EMEABodyText><span lang=EN-GB>No overall differences in safety or
efficacy were reported between elderly (&#8805;&nbsp;65&nbsp;years) and younger
patients (&lt;&nbsp;65&nbsp;years). </span><span lang=EN-GB>Data from patients
75&nbsp;years of age or older are too limited to draw conclusions on this
population.</span></p>

<p class=EMEABodyText><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB>Paediatric
population</span></u></p>

<p class=EMEABodyText><span lang=EN-GB>The European Medicines Agency has
deferred the obligation to submit the results of studies with nivolumab in all
subsets of the paediatric population in the treatment of malignant solid
tumours (see section&nbsp;4.2 for information on paediatric use).</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading2><span lang=EN-GB>5.2&nbsp;&nbsp;&nbsp;&nbsp; Pharmacokinetic
properties</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><i><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></i></p>

<p class=EMEABodyText><span lang=EN-GB>The pharmacokinetics (PK) of nivolumab
is linear in the dose range of&nbsp;0.1&nbsp;to&nbsp;10&nbsp;mg/kg. The
geometric mean clearance (CL), terminal half&#8209;life, and average exposure
at steady state at 3&nbsp;mg/kg every&nbsp;2&nbsp;weeks of nivolumab
were&nbsp;9.5&nbsp;mL/h,&nbsp;26.7&nbsp;days, and 75.3&nbsp;</span><span
lang=EN-GB style='font-family:Symbol'>m</span><span lang=EN-GB>g/mL,
respectively, based on a population PK analysis.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Nivolumab CL increased with increasing
body weight. Body weight normalised dosing produced approximately uniform
steady&#8209;state trough concentration over a wide range of body weights (34&#8209;162&nbsp;kg).
</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>The metabolic pathway of nivolumab has
not been characterised. Nivolumab is expected to be degraded into small
peptides and amino acids via catabolic pathways in the same manner as
endogenous IgG.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB>Special
populations</span></u></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>A population PK analysis suggested no difference
in CL of nivolumab based on age, gender, race, tumour type, tumour size, and
hepatic impairment. Although ECOG status, baseline glomerular filtration rate
(GFR), albumin, body weight, and mild hepatic impairment had an effect on
nivolumab CL, the effect was not clinically meaningful.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><i><u><span lang=EN-GB>Renal
impairment</span></u></i></p>

<p class=EMEABodyText><span lang=EN-GB>The effect of renal impairment on the CL
of nivolumab was evaluated in patients with mild (GFR&nbsp;&lt;&nbsp;90
and&nbsp;&#8805;&nbsp;60&nbsp;mL/min/1.73&nbsp;m<sup>2</sup>;
n&nbsp;=&nbsp;379), moderate (GFR&nbsp;&lt;&nbsp;60
and&nbsp;&#8805;&nbsp;30&nbsp;mL/min/1.73&nbsp;m<sup>2</sup>;
n&nbsp;=&nbsp;179), or severe (GFR&nbsp;&lt;&nbsp;30
and&nbsp;&#8805;&nbsp;15&nbsp;mL/min/1.73&nbsp;m<sup>2</sup>; n&nbsp;=&nbsp;2)
renal impairment compared to patients with normal renal function
(GFR&nbsp;&#8805;&nbsp;90&nbsp;mL/min/1.73&nbsp;m<sup>2</sup>;
n&nbsp;=&nbsp;342) in population PK analyses. No clinically important
differences in the CL of nivolumab were found between patients with mild or
moderate renal impairment and patients with normal renal function. Data from
patients with severe renal impairment are too limited to draw conclusions on
this population (see section&nbsp;4.2). </span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><i><u><span lang=EN-GB>Hepatic
impairment</span></u></i></p>

<p class=EMEABodyText><span lang=EN-GB>The effect of hepatic impairment on the
CL of nivolumab was evaluated in patients with mild hepatic impairment (total
bilirubin&nbsp;1.0&nbsp;&times;&nbsp;to&nbsp;1.5&nbsp;&times;&nbsp;ULN or AST&nbsp;&gt;&nbsp;ULN
as defined using the National Cancer Institute criteria of hepatic dysfunction;
n&nbsp;=&nbsp;92) compared to patients with normal hepatic function (total
bilirubin and AST&nbsp;&#8804;&nbsp;ULN; n&nbsp;=&nbsp;804) in the population
PK analyses. No clinically important differences in the CL of nivolumab were
found between patients with mild hepatic impairment and normal hepatic
function. Nivolumab has not been studied in patients with moderate (total
bilirubin&nbsp;&gt;&nbsp;1.5&nbsp;&times;&nbsp;to&nbsp;3&nbsp;&times;&nbsp;ULN
and any AST) or severe hepatic impairment (total bilirubin&nbsp;&gt;&nbsp;3&nbsp;&times;&nbsp;ULN
and any AST) (see section&nbsp;4.2).</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading2><span lang=EN-GB>5.3&nbsp;&nbsp;&nbsp;&nbsp; Preclinical
safety data</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='font-size:11.5pt;color:black'>Blockade
of PD&#8209;L1 signalling has been shown in murine models of pregnancy to
disrupt tolerance to the foetus and to increase foetal loss. </span><span
lang=EN-GB>The effects of nivolumab on prenatal and postnatal development were
evaluated in monkeys that received nivolumab twice weekly from the onset of
organogenesis in the first trimester through delivery, at exposure levels
either&nbsp;8&nbsp;or&nbsp;35&nbsp;times higher than those observed at the
clinical dose of&nbsp;3&nbsp;mg/kg of nivolumab (based on AUC). </span><span
lang=EN-GB>There was a </span><span lang=EN-GB>dose&#8209;dependent increase in
foetal losses and increased neonatal mortality </span><span lang=EN-GB>beginning
in the third trimester</span><span lang=EN-GB>.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>The remaining offspring of nivolumab&#8209;treated
females survived to scheduled termination, with no treatment&#8209;related
clinical signs, alterations to normal development, organ&#8209;weight effects,
or gross and microscopic pathology changes. Results for growth indices, as well
as teratogenic, neurobehavioral, immunological, and clinical pathology
parameters throughout the 6&#8209;month postnatal period were comparable to the
control group. However, b</span><span lang=EN-GB style='font-size:11.5pt;
color:black'>ased on its mechanism of action, foetal exposure to nivolumab may
increase the risk of developing immune&#8209;related disorders or altering the
normal immune response and immune&#8209;related disorders have been reported in
PD&#8209;1 knockout mice.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Fertility studies have not been
performed with </span><span lang=EN-GB>nivolumab</span><span lang=EN-GB>.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading1><span lang=EN-GB>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PHARMACEUTICAL
PARTICULARS</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading2><span lang=EN-GB>6.1&nbsp;&nbsp;&nbsp;&nbsp; List of
excipients</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Sodium citrate dihydrate</span></p>

<p class=EMEABodyText><span lang=EN-GB>Sodium chloride</span></p>

<p class=EMEABodyText><span lang=EN-GB>Mannitol (E421)</span></p>

<p class=EMEABodyText><span lang=EN-GB>Pentetic acid (diethylenetriaminepentaacetic
acid)</span></p>

<p class=EMEABodyText><span lang=EN-GB>Polysorbate&nbsp;80</span></p>

<p class=EMEABodyText><span lang=EN-GB>Sodium hydroxide (for pH adjustment)</span></p>

<p class=EMEABodyText><span lang=EN-GB>Hydrochloric acid (for pH adjustment)</span></p>

<p class=EMEABodyText><span lang=EN-GB>Water for injections</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading2><span lang=EN-GB>6.2&nbsp;&nbsp;&nbsp;&nbsp; Incompatibilities</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>In the absence of compatibility studies,
this medicinal product must not be mixed with other medicinal products. Nivolumab&nbsp;BMS
should not be infused concomitantly in the same intravenous line with other
medicinal products.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading2><span lang=EN-GB>6.3&nbsp;&nbsp;&nbsp;&nbsp; Shelf life</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB>Unopened
vial</span></u></p>

<p class=EMEABodyText><span lang=EN-GB>2&nbsp;years.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB>After opening</span></u></p>

<p class=EMEABodyTextIndent style='margin-left:0in;text-indent:0in'><span
lang=EN-GB>From a microbiological point of view, once opened, the medicinal
product should be infused or diluted and infused immediately.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyTextIndent style='margin-left:0in;text-indent:0in'><u><span
lang=EN-GB>After preparation of infusion</span></u><span lang=EN-GB> </span></p>

<p class=EMEABodyText><span lang=EN-GB>From a microbiological point of view,
the product should be used immediately.</span></p>

<p class=EMEABodyText><span lang=EN-GB>If not used immediately, chemical and
physical in-use stability of Nivolumab&nbsp;BMS has been demonstrated for
24&nbsp;hours at&nbsp;2&ordm;C to&nbsp;8&ordm;C protected from light and a
maximum of 4&nbsp;hours at 20&deg;C-25&deg;C and room light (this 4-hour period
of the total 24&nbsp;hours should be inclusive of the product administration
period).</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading2><span lang=EN-GB>6.4&nbsp;&nbsp;&nbsp;&nbsp; Special
precautions for storage</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Store in a refrigerator (2&deg;C&#8209;8&deg;C).</span></p>

<p class=EMEABodyText><span lang=EN-GB>Do not freeze.</span></p>

<p class=EMEABodyText><span lang=EN-GB>Store in the original package in order
to protect from light.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>For storage conditions after preparation
of the infusion, see section&nbsp;6.3.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading2><span lang=EN-GB>6.5&nbsp;&nbsp;&nbsp;&nbsp; Nature and
contents of container</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>4&nbsp;mL of concentrate in a&nbsp;10&nbsp;mL
vial (Type&nbsp;I&nbsp;glass) with a stopper (coated butyl rubber) and a dark
blue flip&#8209;off seal (aluminium). Pack size of&nbsp;1&nbsp;vial.</span></p>

<p class=EMEABodyText><span lang=EN-GB>10&nbsp;mL of concentrate in a&nbsp;10&nbsp;mL
vial (Type&nbsp;I&nbsp;glass) with a stopper (coated butyl rubber) and a grey flip&#8209;off
seal (aluminium). Pack size of 1&nbsp;vial.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Not all pack sizes may be marketed.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading2><a name="OLE_LINK1"><span lang=EN-GB>6.6&nbsp;&nbsp;&nbsp;&nbsp; Special
precautions for disposal and other handling</span></a></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Preparation should be performed by
trained personnel in accordance with good practices rules, especially with
respect to asepsis.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB>Preparation
and administration</span></u></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><i><u><span lang=EN-GB>Calculating
the dose</span></u></i></p>

<p class=EMEABodyText><span lang=EN-GB>The prescribed dose for the patient is
given in mg/kg. Based on this prescribed dose, calculate the total dose to be
given. More than one vial of </span><span lang=EN-GB>Nivolumab&nbsp;BMS </span><span
lang=EN-GB>concentrate may be needed to give the total dose for the patient.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyTextIndent><span lang=EN-GB style='font-family:Wingdings'>&sect;<span
style='font:7.0pt "Times New Roman"'>&nbsp; </span></span><span lang=EN-GB>The
total nivolumab dose in mg&nbsp;=&nbsp;the patient&#8217;s weight in kg&nbsp;&times;&nbsp;the
prescribed dose in mg/kg. </span></p>

<p class=EMEABodyTextIndent><span lang=EN-GB style='font-family:Wingdings'>&sect;<span
style='font:7.0pt "Times New Roman"'>&nbsp; </span></span><span lang=EN-GB>The
volume of Nivolumab&nbsp;BMS concentrate to prepare the dose (mL)&nbsp;=&nbsp;the
total dose in mg, divided by&nbsp;10 (the Nivolumab&nbsp;BMS concentrate
strength is&nbsp;10&nbsp;mg/mL). </span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><i><u><span lang=EN-GB>Preparing
the infusion</span></u></i></p>

<p class=EMEABodyText><span lang=EN-GB>Take care to ensure aseptic handling
when you prepare the infusion. The infusion should be prepared in a laminar
flow hood or safety cabinet using standard precautions for the safe handling of
intravenous agents.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Nivolumab&nbsp;BMS</span><span
lang=EN-GB> can be used for intravenous administration either:</span></p>

<p class=EMEABodyTextIndent style='margin-left:27.0pt;text-indent:-27.0pt;
text-autospace:none'><span lang=EN-GB style='font-family:Wingdings'>&sect;<span
style='font:7.0pt "Times New Roman"'>&nbsp; </span></span><span lang=EN-GB>without
dilution, after transfer to an infusion container using an appropriate sterile
syringe;</span><span lang=EN-GB> </span><span lang=EN-GB>or</span></p>

<p class=EMEABodyTextIndent style='text-autospace:none'><span lang=EN-GB
style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><span lang=EN-GB>after diluting to concentrations as low as&nbsp;1&nbsp;mg/</span><span
lang=EN-GB>mL</span><span lang=EN-GB>. The final infusion concentration should
range between&nbsp;1&nbsp;and&nbsp;10&nbsp;mg/</span><span lang=EN-GB>mL</span><span
lang=EN-GB>. </span><span lang=EN-GB>Nivolumab&nbsp;BMS </span><span
lang=EN-GB>concentrate may be diluted with either:</span><span lang=EN-GB> </span></p>

<p class=EMEABodyTextIndent style='margin-left:55.35pt;text-indent:-27.0pt;
text-autospace:none'><span lang=EN-GB style='font-family:Wingdings'>&sect;<span
style='font:7.0pt "Times New Roman"'>&nbsp; </span></span><span lang=EN-GB>sodium
chloride&nbsp;9&nbsp;mg/</span><span lang=EN-GB>mL</span><span lang=EN-GB>
(0.9%) solution for injection; or</span></p>

<p class=EMEABodyTextIndent style='margin-left:55.35pt;text-indent:-27.0pt;
text-autospace:none'><span lang=EN-GB style='font-family:Wingdings'>&sect;<span
style='font:7.0pt "Times New Roman"'>&nbsp; </span></span><span lang=EN-GB>50&nbsp;mg/</span><span
lang=EN-GB>mL</span><span lang=EN-GB> (5%) glucose solution for injection.</span><span
lang=EN-GB> </span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>STEP 1</span></p>

<p class=EMEABodyTextIndent><span lang=EN-GB style='font-family:Wingdings'>&sect;<span
style='font:7.0pt "Times New Roman"'>&nbsp; </span></span><span lang=EN-GB>Inspect
the Nivolumab&nbsp;BMS concentrate for particulate matter or discoloration. Do
not shake the vial. Nivolumab&nbsp;BMS concentrate is a clear to opalescent,
colourless to pale yellow liquid that may contain few light particles. </span></p>

<p class=EMEABodyTextIndent><span lang=EN-GB style='font-family:Wingdings'>&sect;<span
style='font:7.0pt "Times New Roman"'>&nbsp; </span></span><span lang=EN-GB>Withdraw
the required volume of Nivolumab&nbsp;BMS concentrate using an appropriate
sterile syringe. </span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>STEP 2</span></p>

<p class=EMEABodyTextIndent><span lang=EN-GB style='font-family:Wingdings'>&sect;<span
style='font:7.0pt "Times New Roman"'>&nbsp; </span></span><span lang=EN-GB>Transfer
the concentrate into a sterile, evacuated glass bottle or intravenous container
(PVC or polyolefin). </span></p>

<p class=EMEABodyTextIndent><span lang=EN-GB style='font-family:Wingdings'>&sect;<span
style='font:7.0pt "Times New Roman"'>&nbsp; </span></span><span lang=EN-GB>If
applicable, dilute with the required volume of sodium chloride&nbsp;9&nbsp;mg/mL
(0.9%) solution for injection or&nbsp;50&nbsp;mg/mL (5%) glucose solution for
injection. Gently mix the infusion by manual rotation. Do not shake.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><i><u><span lang=EN-GB>Administration</span></u></i></p>

<p class=EMEABodyText><span lang=EN-GB>Nivolumab&nbsp;BMS </span><span
lang=EN-GB>infusion must not be administered as an intravenous push or bolus
injection.</span></p>

<p class=EMEABodyText><span lang=EN-GB>Administer the Nivolumab&nbsp;BMS infusion
intravenously over a period of&nbsp;60&nbsp;minutes.</span></p>

<p class=EMEABodyText><span lang=EN-GB>Nivolumab&nbsp;BMS </span><span
lang=EN-GB>infusion should not be infused at the same time in the same
intravenous line with other agents. Use a separate infusion line for the
infusion.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Use an infusion set and an in&#8209;line,
sterile, non&#8209;pyrogenic, low protein binding filter (pore size
of&nbsp;0.2&nbsp;&#956;m to&nbsp;1.2 &#956;m).</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Nivolumab&nbsp;BMS </span><span
lang=EN-GB>infusion is compatible with PVC and polyolefin containers, glass
bottles, PVC</span><span lang=EN-GB> </span><span lang=EN-GB>infusion sets and
in-line filters with polyethersulfone membranes with pore sizes
of&nbsp;0.2&nbsp;&micro;m to 1.2&nbsp;&micro;m.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>After administration of the nivolumab dose,
flush the line with sodium chloride&nbsp;9&nbsp;mg/mL (0.9%) solution for
injection or&nbsp;50&nbsp;mg/mL (5%) glucose solution for injection.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><i><u><span lang=EN-GB>Disposal</span></u></i></p>

<p class=EMEABodyText><span lang=EN-GB>Do not store any unused portion of the
infusion solution for reuse. </span><span lang=EN-GB>Any unused medicinal
product or waste material should be disposed of in accordance with local
requirements.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading1><span lang=EN-GB>7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; MARKETING
AUTHORISATION HOLDER</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAAddress><span lang=EN-GB>Bristol&#8209;Myers Squibb Pharma EEIG<br>
Uxbridge Business Park<br>
Sanderson Road<br>
Uxbridge UB8&nbsp;1DH<br>
United Kingdom<br>
<br>
</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading1><span lang=EN-GB>8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; MARKETING
AUTHORISATION NUMBER(S)</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>EU/1/15/1026/001-002</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading1><span lang=EN-GB>9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; DATE
OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading1><span lang=EN-GB>10.&nbsp;&nbsp;&nbsp;&nbsp; DATE OF
REVISION OF THE TEXT</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Detailed information on this medicinal
product is available on the website of the European Medicines Agency </span><span
lang=EN-GB><a href="http://www.ema.europa.eu">http://www.ema.europa.eu</a></span></p>

<span class=MsoHyperlink><b><span lang=EN-GB style='font-size:11.0pt;
font-family:"Times New Roman",serif'><br clear=all style='page-break-before:
always'>
</span></b></span>

<p class=EMEATitle><a name="_GoBack"></a><span class=MsoHyperlink><span
lang=EN-GB style='color:windowtext'><span style='text-decoration:none'>&nbsp;</span></span></span></p>

<p class=EMEATitle><span class=MsoHyperlink><span lang=EN-GB style='color:windowtext'><span
 style='text-decoration:none'>&nbsp;</span></span></span></p>

<p class=EMEATitle><span class=MsoHyperlink><span lang=EN-GB style='color:windowtext'><span
 style='text-decoration:none'>&nbsp;</span></span></span></p>

<p class=EMEATitle><span class=MsoHyperlink><span lang=EN-GB style='color:windowtext'><span
 style='text-decoration:none'>&nbsp;</span></span></span></p>

<p class=EMEATitle><span class=MsoHyperlink><span lang=EN-GB style='color:windowtext'><span
 style='text-decoration:none'>&nbsp;</span></span></span></p>

<p class=EMEATitle><span class=MsoHyperlink><span lang=EN-GB style='color:windowtext'><span
 style='text-decoration:none'>&nbsp;</span></span></span></p>

<p class=EMEATitle><span class=MsoHyperlink><span lang=EN-GB style='color:windowtext'><span
 style='text-decoration:none'>&nbsp;</span></span></span></p>

<p class=EMEATitle><span class=MsoHyperlink><span lang=EN-GB style='color:windowtext'><span
 style='text-decoration:none'>&nbsp;</span></span></span></p>

<p class=EMEATitle><span class=MsoHyperlink><span lang=EN-GB style='color:windowtext'><span
 style='text-decoration:none'>&nbsp;</span></span></span></p>

<p class=EMEATitle><span class=MsoHyperlink><span lang=EN-GB style='color:windowtext'><span
 style='text-decoration:none'>&nbsp;</span></span></span></p>

<p class=EMEATitle><span class=MsoHyperlink><span lang=EN-GB style='color:windowtext'><span
 style='text-decoration:none'>&nbsp;</span></span></span></p>

<p class=EMEATitle><span class=MsoHyperlink><span lang=EN-GB style='color:windowtext'><span
 style='text-decoration:none'>&nbsp;</span></span></span></p>

<p class=EMEATitle><span class=MsoHyperlink><span lang=EN-GB style='color:windowtext'><span
 style='text-decoration:none'>&nbsp;</span></span></span></p>

<p class=EMEATitle><span class=MsoHyperlink><span lang=EN-GB style='color:windowtext'><span
 style='text-decoration:none'>&nbsp;</span></span></span></p>

<p class=EMEATitle><span class=MsoHyperlink><span lang=EN-GB style='color:windowtext'><span
 style='text-decoration:none'>&nbsp;</span></span></span></p>

<p class=EMEATitle><span class=MsoHyperlink><span lang=EN-GB style='color:windowtext'><span
 style='text-decoration:none'>&nbsp;</span></span></span></p>

<p class=EMEATitle><span class=MsoHyperlink><span lang=EN-GB style='color:windowtext'><span
 style='text-decoration:none'>&nbsp;</span></span></span></p>

<p class=EMEATitle><span class=MsoHyperlink><span lang=EN-GB style='color:windowtext'><span
 style='text-decoration:none'>&nbsp;</span></span></span></p>

<p class=EMEATitle><span class=MsoHyperlink><span lang=EN-GB style='color:windowtext'><span
 style='text-decoration:none'>&nbsp;</span></span></span></p>

<p class=EMEATitle><span class=MsoHyperlink><span lang=EN-GB style='color:windowtext'><span
 style='text-decoration:none'>&nbsp;</span></span></span></p>

<p class=EMEATitle><span class=MsoHyperlink><span lang=EN-GB style='color:windowtext'><span
 style='text-decoration:none'>&nbsp;</span></span></span></p>

<p class=EMEATitle><span class=MsoHyperlink><span lang=EN-GB style='color:windowtext'><span
 style='text-decoration:none'>&nbsp;</span></span></span></p>

<p class=EMEATitle><span class=MsoHyperlink><span lang=EN-GB style='color:windowtext'><span
 style='text-decoration:none'>&nbsp;</span></span></span></p>

<p class=EMEATitle><span lang=EN-GB>ANNEX II</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEATitle align=left style='margin-left:85.05pt;text-align:left;
text-indent:-35.4pt'><span lang=EN-GB>A.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span
lang=EN-GB>MANUFACTURER OF THE BIOLOGICAL ACTIVE SUBSTANCE AND MANUFACTURER
RESPONSIBLE FOR BATCH RELEASE</span></p>

<p class=EMEABodyText style='margin-left:85.05pt;text-indent:-35.4pt'><span
lang=EN-GB>&nbsp;</span></p>

<p class=EMEATitle align=left style='margin-left:85.05pt;text-align:left;
text-indent:-35.4pt'><span lang=EN-GB>B.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; CONDITIONS
OR RESTRICTIONS REGARDING SUPPLY AND USE</span></p>

<p class=EMEABodyText style='margin-left:85.05pt;text-indent:-35.4pt'><span
lang=EN-GB>&nbsp;</span></p>

<p class=EMEATitle align=left style='margin-left:85.05pt;text-align:left;
text-indent:-35.4pt'><span lang=EN-GB>C.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; OTHER
CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION</span></p>

<p class=EMEABodyText style='margin-left:85.05pt;text-indent:-35.4pt'><span
lang=EN-GB>&nbsp;</span></p>

<p class=EMEATitle align=left style='margin-left:85.05pt;text-align:left;
text-indent:-35.4pt'><span lang=EN-GB>D.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; CONDITIONS
OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL
PRODUCT</span></p>

<p class=EMEABodyText style='margin-left:85.05pt;text-indent:-35.4pt'><span
lang=EN-GB>&nbsp;</span></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
text-transform:uppercase'><br clear=all style='page-break-before:always'>
</span></b>

<p class=EMEAHeading1><span lang=EN-GB>A.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; MANUFACTURER
</span><span lang=EN-GB>OF THE BIOLOGICAL ACTIVE SUBSTANCE AND MANUFACTURER
RESPONSIBLE FOR BATCH RELEASE</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB>Name and address of the manufacturer of
the biological active substance</span></u></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAAddress style='page-break-after:avoid'><span lang=EN-GB>Lonza
Biologics, Inc.</span></p>

<p class=EMEAAddress style='page-break-after:avoid'><span lang=EN-GB>101
International Drive</span></p>

<p class=EMEAAddress style='page-break-after:avoid'><span lang=EN-GB>Portsmouth,
New Hampshire</span></p>

<p class=EMEAAddress style='page-break-after:avoid'><span lang=EN-GB>03801</span></p>

<p class=EMEAAddress style='page-break-after:avoid'><span lang=EN-GB>USA</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB>Name and address of the manufacturer
responsible for batch release</span></u></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAAddress><span lang=EN-GB>Bristol&#8209;Myers Squibb S.r.l.</span></p>

<p class=EMEAAddress><span lang=EN-GB>Loc. Fontana del Ceraso</span></p>

<p class=EMEAAddress><span lang=EN-GB>03012&nbsp;Anagni (FR)</span></p>

<p class=EMEAAddress><span lang=EN-GB>Italy</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading1><a name="OLE_LINK2"><span lang=EN-GB>B.</span></a><span
lang=EN-GB>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; CONDITIONS OR RESTRICTIONS REGARDING
SUPPLY AND USE </span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Medicinal product subject to restricted
medical prescription (see Annex I: Summary of Product Characteristics, section
4.2).</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading1><span lang=EN-GB>C. &nbsp;&nbsp;&nbsp;&nbsp; OTHER
CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyTextIndent><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB>Periodic safety update reports</span></b></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>The marketing authorisation holder shall
submit the first periodic safety update report for this product within 6 months
following authorisation. Subsequently, the marketing authorisation holder shall
submit periodic safety update reports for this product in accordance with the
requirements set out in the list of Union reference dates (EURD list) provided
for under Article 107c(7) of Directive 2001/83/EC and published on the European
medicines web-portal.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading1><span lang=EN-GB>D.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; CONDITIONS
OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL
PRODUCT&nbsp; </span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyTextIndent><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB>Risk Management Plan (RMP)</span></b></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>The MAH shall perform the required
pharmacovigilance activities and interventions detailed in the agreed RMP
presented in Module 1.8.2 of the Marketing Authorisation and any agreed
subsequent updates of the RMP.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>An updated RMP should be submitted:</span></p>

<p class=EMEABodyText style='margin-left:28.35pt;text-indent:-14.15pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>At the request of the European Medicines Agency;</span></p>

<p class=EMEABodyText style='margin-left:28.35pt;text-indent:-14.15pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Whenever the risk management system is modified,
especially as the result of new information being received that may lead to a
significant change to the benefit/risk profile or as the result of an important
(pharmacovigilance or risk minimisation) milestone being reached.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>If the dates for submission of a PSUR
and the update of a RMP coincide, they can be submitted at the same time.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyTextIndent><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB>Additional risk minimisation measures </span></b></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Prior to launch of Nivolumab&nbsp;BMS in
each Member State the Marketing Authorisation Holder (MAH) must agree about the
content and format of the educational programme, including communication media,
distribution modalities, and any other aspects of the programme, with the
National Competent Authority. </span></p>

<p class=EMEABodyText><span lang=EN-GB>The educational programme is aimed at
increasing the awareness about the potential immune mediated adverse events
associated with Nivolumab&nbsp;BMS use, how to manage them and to enhance the awareness
of patients or their caregivers on the signs and symptoms relevant to the early
those adverse events.</span></p>

<p class=EMEABodyText><span lang=EN-GB>The MAH shall ensure that in each Member
State where Nivolumab&nbsp;BMS is marketed, all healthcare professionals and
patients/carers who are expected to prescribe and use Nivolumab&nbsp;BMS have
access to/are provided with the following educational package:</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyTextIndent style='margin-left:35.45pt;text-indent:-21.25pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Physician educational material</span></p>

<p class=EMEABodyTextIndent style='margin-left:35.45pt;text-indent:-21.25pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Patient alert card</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><b><span lang=EN-GB>The physician educational material</span></b><span
lang=EN-GB> should contain:</span></p>

<p class=EMEABodyTextIndent style='margin-left:35.45pt;text-indent:-21.25pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>The Summary of Product Characteristics</span></p>

<p class=EMEABodyTextIndent style='margin-left:35.45pt;text-indent:-21.25pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Adverse Reaction Management Guide</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>The </span><span lang=EN-GB>Adverse
Reaction Management Guide shall contain the following key elements:</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:#1D1B11'>&nbsp;</span></p>

<p class=EMEABodyTextIndent style='margin-left:28.35pt;text-indent:-14.15pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Relevant information (e.g. seriousness,
severity, frequency, time to onset, reversibility of the AE as applicable) for
the following safety concerns:</span></p>

<p class=EMEABodyTextIndent style='margin-left:63.8pt;text-indent:-27.8pt'><span
lang=EN-GB style='font-family:"Courier New"'>o<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Immune-related pneumonitis</span></p>

<p class=EMEABodyTextIndent style='margin-left:63.8pt;text-indent:-27.8pt'><span
lang=EN-GB style='font-family:"Courier New"'>o<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Immune-related colitis</span></p>

<p class=EMEABodyTextIndent style='margin-left:63.8pt;text-indent:-27.8pt'><span
lang=EN-GB style='font-family:"Courier New"'>o<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Immune-related hepatitis</span></p>

<p class=EMEABodyTextIndent style='margin-left:63.8pt;text-indent:-27.8pt'><span
lang=EN-GB style='font-family:"Courier New"'>o<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Immune-related nephritis or renal dysfunction</span></p>

<p class=EMEABodyTextIndent style='margin-left:63.8pt;text-indent:-27.8pt'><span
lang=EN-GB style='font-family:"Courier New"'>o<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Immune-related endocrinopathies </span></p>

<p class=EMEABodyTextIndent style='margin-left:63.8pt;text-indent:-27.8pt'><span
lang=EN-GB style='font-family:"Courier New"'>o<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Immune related rash</span></p>

<p class=EMEABodyTextIndent style='margin-left:63.8pt;text-indent:-27.8pt'><span
lang=EN-GB style='font-family:"Courier New"'>o<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Other immune-related ARs</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyTextIndent style='margin-left:28.35pt;text-indent:-14.15pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Details on how to minimise the safety concern
through appropriate monitoring and management</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyTextIndent style='margin-left:28.35pt;text-indent:-14.15pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB>The patient alert card</span></b><span
lang=EN-GB> shall contain the following key messages: </span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyTextIndent style='margin-left:28.35pt;text-indent:-14.15pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>That Nivolumab&nbsp;BMS treatment may increase
the risk of: </span></p>

<p class=EMEABodyTextIndent style='margin-left:63.8pt;text-indent:-27.8pt'><span
lang=EN-GB style='font-family:"Courier New"'>o<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Immune-related pneumonitis</span></p>

<p class=EMEABodyTextIndent style='margin-left:63.8pt;text-indent:-27.8pt'><span
lang=EN-GB style='font-family:"Courier New"'>o<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Immune-related colitis</span></p>

<p class=EMEABodyTextIndent style='margin-left:63.8pt;text-indent:-27.8pt'><span
lang=EN-GB style='font-family:"Courier New"'>o<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Immune-related hepatitis</span></p>

<p class=EMEABodyTextIndent style='margin-left:63.8pt;text-indent:-27.8pt'><span
lang=EN-GB style='font-family:"Courier New"'>o<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Immune-related nephritis or renal dysfunction</span></p>

<p class=EMEABodyTextIndent style='margin-left:63.8pt;text-indent:-27.8pt'><span
lang=EN-GB style='font-family:"Courier New"'>o<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Immune-related endocrinopathies </span></p>

<p class=EMEABodyTextIndent style='margin-left:63.8pt;text-indent:-27.8pt'><span
lang=EN-GB style='font-family:"Courier New"'>o<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Immune related rash</span></p>

<p class=EMEABodyTextIndent style='margin-left:63.8pt;text-indent:-27.8pt'><span
lang=EN-GB style='font-family:"Courier New"'>o<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Other immune-related ARs</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyTextIndent style='margin-left:28.35pt;text-indent:-14.15pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Signs or symptoms of the safety concern and when
to seek attention from a HCP</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyTextIndent style='margin-left:28.35pt;text-indent:-14.15pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Contact details of the Nivolumab&nbsp;BMS prescriber
</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyTextIndent style='page-break-after:avoid'><span lang=EN-GB
style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB>Obligation to conduct post-authorisation
measures </span></b></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>The MAH
shall complete, within the stated timeframe, the below measures:</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0
 style='margin-left:1.2pt;border-collapse:collapse'>
 <tr style='page-break-inside:avoid;height:21.5pt'>
  <td width=462 style='width:346.35pt;border:solid black 1.0pt;background:white;
  padding:0in 4.25pt 0in 4.25pt;height:21.5pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><b><span lang=EN-GB>Description</span></b></p>
  </td>
  <td width=142 style='width:106.3pt;border:solid black 1.0pt;border-left:none;
  background:white;padding:0in 4.25pt 0in 4.25pt;height:21.5pt'>
  <p class=EMEABodyText><span lang=EN-GB style='color:black'>Due date</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:63.25pt'>
  <td width=462 style='width:346.35pt;border:solid black 1.0pt;border-top:none;
  background:white;padding:0in 4.25pt 0in 4.25pt;height:63.25pt'>
  <p class=EMEABodyText><span lang=EN-GB style='color:black'>1. </span><span
  lang=EN-GB style='color:black'>Post-authorisation efficacy study (PAES): </span><span
  lang=EN-GB style='color:black'>The MAH should submit an updated OS data for
  Study CA209017: </span><span style='color:black'>a Phase&nbsp;3, randomized
  study of nivolumab vs docetaxel in subjects with advanced or metastatic
  squamous NSCLC who have experienced disease progression during or after one
  prior platinum doublet-based chemotherapy regimen</span><span lang=EN-GB
  style='color:black'>. </span></p>
  </td>
  <td width=142 style='width:106.3pt;border-top:none;border-left:none;
  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;background:
  white;padding:0in 4.25pt 0in 4.25pt;height:63.25pt'>
  <p class=EMEABodyText><span lang=EN-GB style='color:black'>The updated data
  should be submitted by 31</span><span class=EMEASuperscript><span lang=EN-GB
  style='color:black'>st </span></span><span lang=EN-GB style='color:black'>December
  2015</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:303.7pt'>
  <td width=462 style='width:346.35pt;border:solid black 1.0pt;border-top:none;
  background:white;padding:0in 4.25pt 0in 4.25pt;height:303.7pt'>
  <p class=EMEABodyText><span lang=EN-GB style='color:black'>2. The value of
  biomarkers to predict the efficacy of nivolumab should be further explored,
  specifically:</span></p>
  <p class=EMEABodyText style='margin-left:27.4pt;text-indent:-14.15pt'><span
  lang=EN-GB>1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp; </span></span><span
  lang=EN-GB style='color:black'>To continue the exploration of the optimal
  cut-off for PD-L1 positivity based on current assay method used to further
  elucidate its value as predictive of nivolumab efficacy. These analyses will
  be conducted in Studies CA 209037 and CA209066 in patients with advanced
  melanoma.</span></p>
  <p class=EMEABodyText style='margin-left:27.4pt;text-indent:-14.15pt'><span
  lang=EN-GB>2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp; </span></span><span
  lang=EN-GB style='color:black'>To further investigate the value biomarkers
  other than PD-L1 expression status at tumour cell membrane level by IHC (e.g.,
  other methods / assays, and associated cut-offs, that might prove more
  sensitive and specific in predicting response to treatment based on PD-L1,
  PD-L2, tumour infiltrating lymphocytes with measurement of CD8+T density, RNA
  signature, etc.) as predictive of nivolumab efficacy. These additional
  biomarker analyses are occurring in the context of Study CA209-038 and Study
  CA209-066. </span></p>
  <p class=EMEABodyText style='margin-left:27.4pt;text-indent:-14.15pt'><span
  lang=EN-GB>3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp; </span></span><span
  lang=EN-GB style='color:black'>To further investigate at post-approval the
  relation between PDL-1 and PDL-2 expression in Phase 1 (CA209009, CA209038
  and CA209064).</span></p>
  <p class=EMEABodyText style='margin-left:27.4pt;text-indent:-14.15pt'><span
  lang=EN-GB>4.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp; </span></span><span
  lang=EN-GB style='color:black'>To further investigate the associative
  analyses between PDL-1 and PDL-2 expression conducted in Study CA209-066.</span></p>
  <p class=EMEABodyText style='margin-left:27.4pt;text-indent:-14.15pt'><span
  lang=EN-GB>5.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp; </span></span><span
  lang=EN-GB style='color:black'>To further investigate at post-approval the
  possible change in PD-L1 status of the tumour during treatment and/or tumour
  progression in Studies CA209-009, CA209-038 and CA209-064. </span></p>
  <p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=142 style='width:106.3pt;border-top:none;border-left:none;
  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;background:
  white;padding:0in 4.25pt 0in 4.25pt;height:303.7pt'>
  <p class=EMEABodyText><span lang=EN-GB style='color:black'>30</span><span
  class=EMEASuperscript><span lang=EN-GB style='color:black'>th</span></span><span
  lang=EN-GB style='color:black'> September 2015</span></p>
  <p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>
  <p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>
  <p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>
  <p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>
  <p class=EMEABodyText><span lang=EN-GB style='color:black'>30</span><span
  class=EMEASuperscript><span lang=EN-GB style='color:black'>th</span></span><span
  lang=EN-GB style='color:black'> September 2017</span></p>
  <p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>
  <p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>
  <p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>
  <p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>
  <p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>
  <p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>
  <p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>
  <p class=EMEABodyText><span lang=EN-GB style='color:black'>31</span><span
  class=EMEASuperscript><span lang=EN-GB style='color:black'>st</span></span><span
  lang=EN-GB style='color:black'> March 2017</span></p>
  <p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>
  <p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>
  <p class=EMEABodyText><span lang=EN-GB style='color:black'>31</span><span
  class=EMEASuperscript><span lang=EN-GB style='color:black'>st</span></span><span
  lang=EN-GB style='color:black'> December 2017</span></p>
  <p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>
  <p class=EMEABodyText><span lang=EN-GB style='color:black'>30</span><span
  class=EMEASuperscript><span lang=EN-GB style='color:black'>th</span></span><span
  lang=EN-GB style='color:black'> September 2017</span></p>
  <p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
</table>

<p class=EMEABodyText><span class=MsoHyperlink><span lang=EN-GB
style='color:black'><span style='text-decoration:none'>&nbsp;</span></span></span></p>

<span class=MsoHyperlink><span lang=EN-GB style='font-size:11.0pt;font-family:
"Times New Roman",serif;color:black'><br clear=all style='page-break-before:
always'>
</span></span>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEATitle><span lang=EN-GB>ANNEX</span><span lang=EN-GB
style='font-weight:normal'> </span><span lang=EN-GB>III</span></p>

<p class=EMEABodyText><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=EMEATitle><span lang=EN-GB>LABELLING</span><span lang=EN-GB
style='font-weight:normal'> </span><span lang=EN-GB>AND</span><span lang=EN-GB
style='font-weight:normal'> </span><span lang=EN-GB>PACKAGE</span><span
lang=EN-GB style='font-weight:normal'> </span><span lang=EN-GB>LEAFLET</span></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></b>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEATitle><span lang=EN-GB>A. LABELLING</span></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
text-transform:uppercase'><br clear=all style='page-break-before:always'>
</span></b>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=EN-GB>PARTICULARS TO APPEAR ON THE OUTER
PACKAGING</span></p>

<p class=EMEATitlePAC><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEATitlePAC><span lang=EN-GB>OUTER CARTON</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=EN-GB>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NAME
OF THE MEDICINAL PRODUCT&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Nivolumab&nbsp;BMS&nbsp;10&nbsp;mg/mL concentrate
for solution for infusion</span></p>

<p class=EMEABodyText><span lang=EN-GB>nivolumab</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=EN-GB>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; STATEMENT
OF ACTIVE SUBSTANCE(S)</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Each mL of concentrate contains&nbsp;10&nbsp;mg
of nivolumab.</span></p>

<p class=EMEABodyText><span lang=EN-GB>Each vial of 4&nbsp;mL contains&nbsp;40&nbsp;mg
of nivolumab.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='background:silver'>Each vial of
10&nbsp;mL contains&nbsp;100&nbsp;mg of nivolumab.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=EN-GB>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; LIST
OF EXCIPIENTS</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Excipients: sodium citrate dihydrate,
sodium chloride, mannitol&nbsp;(E421), pentetic acid, polysorbate&nbsp;80,
sodium hydroxide, hydrochloric acid, water for injections.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='background:silver'>See leaflet
for further information.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='background:silver'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=EN-GB>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PHARMACEUTICAL
FORM AND CONTENTS</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='background:silver'>Concentrate
for solution for infusion.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>40&nbsp;mg/4&nbsp;mL</span></p>

<p class=EMEABodyText><span lang=EN-GB style='background:silver'>100&nbsp;mg/10&nbsp;mL</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>1&nbsp;vial</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=EN-GB>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; METHOD
AND ROUTE(S) OF ADMINISTRATION</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Read the package leaflet before use.</span></p>

<p class=EMEABodyText><span lang=EN-GB>Intravenous use.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL WARNING THAT THE
MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Keep out of the sight and reach of
children.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=EN-GB>7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; OTHER
SPECIAL WARNING(S), IF NECESSARY</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>For single use only.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=EN-GB>8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; EXPIRY
DATE</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>EXP</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=EN-GB>9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL
STORAGE CONDITIONS</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Store in a refrigerator.</span></p>

<p class=EMEABodyText><span lang=EN-GB>Do not freeze.</span></p>

<p class=EMEABodyText><span lang=EN-GB>Store in the original package in order
to protect from light.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>10.&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL PRECAUTIONS FOR DISPOSAL OF
UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL
PRODUCTS, IF APPROPRIATE</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=EN-GB>11.&nbsp;&nbsp;&nbsp;&nbsp; NAME AND
ADDRESS OF THE MARKETING AUTHORISATION HOLDER</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Bristol&#8209;Myers Squibb Pharma EEIG</span></p>

<p class=EMEABodyText><span lang=EN-GB>Uxbridge Business Park</span></p>

<p class=EMEABodyText><span lang=EN-GB>Sanderson Road</span></p>

<p class=EMEABodyText><span lang=EN-GB>Uxbridge UB8&nbsp;1DH</span></p>

<p class=EMEABodyText><span lang=EN-GB>United Kingdom<i><br>
<br>
</i></span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=EN-GB>12.&nbsp;&nbsp;&nbsp;&nbsp; MARKETING
AUTHORISATION NUMBER(S) </span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText>EU/1/15/1026/001&nbsp;<span style='background:silver'>40&nbsp;mg
vial</span></p>

<p class=EMEABodyText><span style='background:silver'>EU/1/15/1026/002&nbsp;100&nbsp;mg
vial</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=EN-GB>13.&nbsp;&nbsp;&nbsp;&nbsp; BATCH NUMBER</span></p>

</div>

<p class=EMEABodyText><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=EMEABodyText><span lang=EN-GB>Lot</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=EN-GB>14.&nbsp;&nbsp;&nbsp;&nbsp; GENERAL
CLASSIFICATION FOR SUPPLY</span></p>

</div>

<p class=EMEABodyText><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=EN-GB>15.&nbsp;&nbsp;&nbsp;&nbsp; INSTRUCTIONS
ON USE</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=EN-GB>16.&nbsp;&nbsp;&nbsp;&nbsp; INFORMATION
IN BRAILLE</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black;background:silver'>Justification
for not including Braille accepted</span><span lang=EN-GB style='color:black;
background:#CCCCCC'>.</span></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:black;text-transform:uppercase;background:#CCCCCC'><br clear=all
style='page-break-before:always'>
</span></b>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=EN-GB>minimum PARTICULARS TO APPEAR ON small
IMMEDIATE PACKAGING units</span></p>

<p class=EMEATitlePAC><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEATitlePAC><span lang=EN-GB>VIAL LABEL</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=EN-GB>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NAME
OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Nivolumab&nbsp;BMS&nbsp;10&nbsp;mg/mL
sterile concentrate</span></p>

<p class=EMEABodyText><span lang=EN-GB>nivolumab</span></p>

<p class=EMEABodyText><span lang=EN-GB>IV use</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=EN-GB>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; METHOD
OF ADMINISTRATION</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Read the package leaflet before use.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=EN-GB>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; EXPIRY
DATE</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>EXP</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=EN-GB>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; BATCH
NUMBER</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Lot</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=EN-GB>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; CONTENTS
BY WEIGHT, BY VOLUME OR BY UNIT</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>40&nbsp;mg/4&nbsp;mL</span></p>

<p class=EMEABodyText><span lang=EN-GB style='background:silver'>100&nbsp;mg/10&nbsp;mL</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=EN-GB>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; OTHER</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>For single use only.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='background:#CCCCCC'>&nbsp;</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEATitle><span lang=EN-GB>B. PACKAGE LEAFLET</span></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></b>

<p class=EMEATitle><span lang=EN-GB>Package leaflet: Information for the user</span></p>

<p class=EMEATitle><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEATitle><span lang=EN-GB>Nivolumab&nbsp;BMS&nbsp;10&nbsp;mg/mL concentrate
for solution for infusion</span></p>

<p class=EMEABodyText align=center style='text-align:center'><span lang=EN-GB>nivolumab</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB><img border=0 width=21 height=18
src="Nivolumab%20BMS-3840%20-%20EN%20PI%20clea_files/image006.gif"
alt="BT_1000x858px"></span><span lang=EN-GB>This medicine is subject to
additional monitoring. This will allow quick identification of new safety
information. You can help by reporting any side effects you may get. See the
end of section&nbsp;4 for how to report side effects.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><b><span lang=EN-GB>Read all of this leaflet carefully
before you start using this medicine because it contains important information
for you.</span></b></p>

<p class=EMEABodyText><span lang=EN-GB>Keep this leaflet. You may need to read
it again. </span></p>

<p class=EMEABodyText><span lang=EN-GB>It is important that you keep the Alert
Card with you during treatment.</span></p>

<p class=EMEABodyText><span lang=EN-GB>If you have any further questions, ask
your doctor.</span></p>

<p class=EMEABodyText><span lang=EN-GB>If you get any side effects, talk to
your doctor.</span><span lang=EN-GB> This includes any possible side effects
not listed in this leaflet. See section&nbsp;4.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><b><span lang=EN-GB>What
is in this leaflet</span></b></p>

<p class=EMEABodyText style='page-break-after:avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; What
Nivolumab&nbsp;BMS is and what it is used for </span></p>

<p class=EMEABodyText><span lang=EN-GB>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; What
you need to know before you use Nivolumab&nbsp;BMS</span></p>

<p class=EMEABodyText><span lang=EN-GB>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; How
to use Nivolumab&nbsp;BMS</span></p>

<p class=EMEABodyText><span lang=EN-GB>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Possible
side effects</span></p>

<p class=EMEABodyText><span lang=EN-GB>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; How
to store Nivolumab&nbsp;BMS</span></p>

<p class=EMEABodyText><span lang=EN-GB>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Contents
of the pack and other information</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading3><span lang=EN-GB>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; What
Nivolumab&nbsp;BMS is and what it is used for</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Nivolumab&nbsp;BMS is a medicine used to
treat advanced non-small cell lung cancer (a type of lung cancer) in adults. It
contains the active substance nivolumab, which is a monoclonal antibody, a type
of protein designed to recognise and attach to a specific target substance in
the body. </span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Nivolumab attaches to a target protein
called programmed death&#8209;1 receptor (PD&#8209;1) that can switch off the
activity of T cells (a type of white blood cell that forms part of the immune
system, the body&#8217;s natural defences). By attaching to PD-1, nivolumab
blocks its action and prevents it from switching off your T cells. This helps
increase their activity against the lung cancer cells.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading3><span lang=EN-GB>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; What
you need to know before you use Nivolumab&nbsp;BMS</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=EMEABodyText style='page-break-after:avoid'><b><span lang=EN-GB>You
should not be given Nivolumab&nbsp;BMS</span></b></p>

<p class=EMEABodyTextIndent style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if you are <b>allergic</b> to nivolumab or any
of the other ingredients of this medicine (listed in section&nbsp;6
&quot;Contents of the pack and other information&quot;). <b>Talk to your doctor</b>
if you are not sure.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><b><span lang=EN-GB>Warnings
and precautions</span></b></p>

<p class=EMEABodyText><span lang=EN-GB>Talk to your doctor before using
Nivolumab&nbsp;BMS as it may cause:</span></p>

<p class=EMEABodyTextIndent style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB>Problems with your lungs</span></b><span
lang=EN-GB> such as breathing difficulties or cough. These may be signs of
inflammation of the lungs (pneumonitis <span style='color:black'>or
interstitial lung disease).</span></span></p>

<p class=EMEABodyTextIndent style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB>Diarrhoea</span></b><span lang=EN-GB>
(watery, loose or soft stools) or any symptoms of <b>inflammation of the
intestines</b> (colitis), such as stomach pain and mucus or blood in stool.</span></p>

<p class=EMEABodyTextIndent style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB>Inflammation of the liver (hepatitis).</span></b><span
lang=EN-GB> Signs and symptoms of hepatitis may include abnormal liver function
tests, eye or skin yellowing (jaundice), pain on the right side of your stomach
area, or tiredness.</span></p>

<p class=EMEABodyTextIndent style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB>Inflammation or problems with your kidneys. </span></b><span
lang=EN-GB>Signs and symptoms may include abnormal kidney function tests, or
decreased volume of urine.</span></p>

<p class=EMEABodyTextIndent style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB>Problems with your hormone producing glands</span></b><span
lang=EN-GB> (including the pituitary, the thyroid and adrenal glands) that may
affect how these glands work. Signs and symptoms that these glands are not
working properly may include fatigue (extreme tiredness), weight change or
headache and visual disturbances.</span></p>

<p class=EMEABodyTextIndent style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB>Diabetes </span></b><span lang=EN-GB>(symptoms
include excessive thirst, the passing of a greatly increased amount of urine,
increase in appetite with a loss of weight, feeling tired, drowsy, weak,
depressed, irritable and generally unwell) or <b>diabetic ketoacidosis </b>(acid
in the blood produced from diabetes).</span></p>

<p class=EMEABodyTextIndent style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB>Inflammation of the skin </span></b><span
lang=EN-GB>that can lead to rash and itching.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><b><span lang=EN-GB style='color:black'>Tell your doctor
immediately</span></b><span lang=EN-GB style='color:black'> if you have any of
these signs or symptoms or if they get worse. <b>Do not try to treat your
symptoms with other medicines on your own. </b>Your doctor may</span></p>

<p class=EMEABodyTextIndent style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>give you other medicines in order to prevent complications
and reduce your symptoms,</span></p>

<p class=EMEABodyTextIndent style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>withhold the next dose of Nivolumab&nbsp;BMS,</span></p>

<p class=EMEABodyTextIndent style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>or stop your treatment with Nivolumab&nbsp;BMS
altogether.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Please note that
these signs and symptoms are <b>sometimes delayed</b>, and may develop weeks or
months after your last dose. Before treatment, your doctor will check your
general health. You will also have <b>blood tests</b> during your treatment.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><b><span lang=EN-GB>Check
with your doctor or nurse before you are given Nivolumab&nbsp;BMS if:</span></b></p>

<p class=EMEABodyTextIndent style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>you have been told that your <b>cancer has
spread to your brain</b></span></p>

<p class=EMEABodyTextIndent style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>you have an <b>autoimmune disease</b> (a
condition where the body attacks its own cells);</span></p>

<p class=EMEABodyTextIndent style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>you have any history of <b>inflammation of the
lungs</b>;</span></p>

<p class=EMEABodyTextIndent style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>you have been taken <b>medicines to suppress
your immune system.</b></span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><b><span lang=EN-GB>Children
and adolescents</span></b></p>

<p class=EMEABodyText><span lang=EN-GB>Nivolumab&nbsp;BMS should not be used in
children and adolescents below&nbsp;18&nbsp;years of age.</span></p>

<p class=EMEABodyText><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=EMEABodyText style='page-break-after:avoid'><b><span lang=EN-GB>Other
medicines and Nivolumab&nbsp;BMS</span></b></p>

<p class=EMEABodyText><b><span lang=EN-GB>Before you are given </span><span
lang=EN-GB>Nivolumab&nbsp;BMS</span></b><b><span lang=EN-GB>, tell your doctor </span></b><span
lang=EN-GB>if you are taking any medicines that suppress your immune system,
such as corticosteroids, since these medicines may interfere with the effect of
</span><span lang=EN-GB>Nivolumab&nbsp;BMS</span><span lang=EN-GB>. However,
once you are treated with </span><span lang=EN-GB>Nivolumab&nbsp;BMS</span><span
lang=EN-GB>, your doctor may give you corticosteroids to reduce any possible
side&#8209;effects that you may have during your treatment and this will not
impact the effect of the medicine.</span></p>

<p class=EMEABodyText><b><span lang=EN-GB>Tell your doctor </span></b><span
lang=EN-GB>if you are taking or have recently taken any other medicines. </span><b><span
lang=EN-GB>Do not take any other medicines </span></b><span lang=EN-GB>during
your treatment without talking to your doctor first.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><b><span lang=EN-GB>Pregnancy
and breast&#8209;feeding</span></b></p>

<p class=EMEABodyText><b><span lang=EN-GB>Tell your doctor</span></b><span
lang=EN-GB> if you are pregnant or think you might be, if you are planning to
become pregnant, or if you are breast&#8209;feeding.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><b><span lang=EN-GB>Do not use Nivolumab&nbsp;BMS if you
are pregnant</span></b><span lang=EN-GB> unless your doctor specifically tells
you to. The effects of </span><span lang=EN-GB>Nivolumab&nbsp;BMS</span><span
lang=EN-GB> in pregnant women are not known, but it is possible that the active
substance, nivolumab, could harm an unborn baby.</span></p>

<p class=EMEABodyTextIndent style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>You must use <b>effective contraception</b>
while you are being treated with Nivolumab&nbsp;BMS and for at least 5&nbsp;months
following the last dose of Nivolumab&nbsp;BMS, if you are a woman who could
become pregnant.</span></p>

<p class=EMEABodyTextIndent style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>If you become pregnant while using Nivolumab&nbsp;BMS
<b>tell your doctor</b>.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>It is not known whether nivolumab gets
into breast milk. A risk to the breast&#8209;fed infant cannot be excluded. <b>Ask
your doctor</b> if you can breast&#8209;feed during or after treatment with Nivolumab&nbsp;BMS.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><b><span lang=EN-GB>Driving
and using machines</span></b></p>

<p class=EMEABodyText><span lang=EN-GB>Nivolumab is unlikely to affect your
ability to drive or use machines; however, use caution when performing these
activities until you are sure that nivolumab does not adversely affect you.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><b><span lang=EN-GB>Nivolumab&nbsp;BMS</span><span
lang=EN-GB> contains sodium</span></b></p>

<p class=EMEABodyText><b><span lang=EN-GB>Tell your doctor </span></b><span
lang=EN-GB>if you are on a low&#8209;sodium (low&#8209;salt) diet before you
are given </span><span lang=EN-GB>Nivolumab&nbsp;BMS</span><span lang=EN-GB>. This
medicine contains&nbsp;2.5&nbsp;mg sodium per </span><span lang=EN-GB>mL</span><span
lang=EN-GB> of concentrate.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>You will also find this information in
the Patient Alert Card you have been given by your doctor. It is important that
you keep this Alert Card and show it to your partner or caregivers.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading3><span lang=EN-GB>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; H</span><span
lang=EN-GB>ow to use Nivolumab&nbsp;BMS</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><b><span lang=EN-GB>How
much </span><span lang=EN-GB>Nivolumab&nbsp;BMS</span></b><b><span lang=EN-GB>
is given</span></b></p>

<p class=EMEABodyText><span lang=EN-GB>The amount of </span><span lang=EN-GB>Nivolumab&nbsp;BMS</span><span
lang=EN-GB> you will be given will be calculated based on your body weight. The
</span><span lang=EN-GB>recommended</span><span lang=EN-GB> dose
is&nbsp;3&nbsp;mg of nivolumab per kilogram of your body weight.</span></p>

<p class=EMEABodyText><span lang=EN-GB>Depending on your dose, the appropriate
amount of </span><span lang=EN-GB>Nivolumab&nbsp;BMS</span><span lang=EN-GB> will
be diluted with sodium chloride&nbsp;9&nbsp;mg/mL&nbsp;(0.9%) solution for
injection or&nbsp;glucose 50&nbsp;mg/mL&nbsp;(5%) solution for injection before
use. More than one vial of </span><span lang=EN-GB>Nivolumab&nbsp;BMS</span><span
lang=EN-GB> may be necessary to obtain the required dose.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><b><span lang=EN-GB>How
Nivolumab&nbsp;BMS is given</span></b></p>

<p class=EMEABodyText><span lang=EN-GB>You will receive treatment with </span><span
lang=EN-GB>Nivolumab&nbsp;BMS</span><span lang=EN-GB> in a hospital or clinic,
under the supervision of an experienced doctor.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Nivolumab&nbsp;BMS</span><span
lang=EN-GB> will be given to you as an infusion (a drip) into a vein
(intravenously) over a period of&nbsp;60&nbsp;minutes, every&nbsp;2&nbsp;weeks.
Your doctor will continue giving you </span><span lang=EN-GB>Nivolumab&nbsp;BMS</span><span
lang=EN-GB> for as long as you keep benefitting from it or until you no longer
tolerate the treatment.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><b><span lang=EN-GB>If you
miss a dose of Nivolumab&nbsp;BMS</span></b></p>

<p class=EMEABodyText><span lang=EN-GB>It is very important for you to keep all
your appointments to receive </span><span lang=EN-GB>Nivolumab&nbsp;BMS</span><span
lang=EN-GB>. If you miss an appointment, ask your doctor when to schedule your
next dose.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><b><span lang=EN-GB>If you
stop using Nivolumab&nbsp;BMS</span></b></p>

<p class=EMEABodyText><span lang=EN-GB>Stopping your treatment may stop the
effect of the medicine. Do not stop treatment with </span><span lang=EN-GB>Nivolumab&nbsp;BMS</span><span
lang=EN-GB> unless you have discussed this with your doctor.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>If you have any further questions about
your treatment or on the use of this medicine, ask your doctor.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading3><span lang=EN-GB>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Possible
side effects</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Like all medicines, this medicine can
cause side effects, although not everybody gets them. Your doctor will discuss
these with you and will explain the risks and benefits of your treatment.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><b><span lang=EN-GB>Be aware of important symptoms of
inflammation.</span></b><span lang=EN-GB> Nivolumab&nbsp;BMS acts on your
immune system and may cause inflammation in parts of your body. Inflammation
may cause serious damage to your body and some inflammatory conditions may be
life&#8209;threatening and need treatment or withdrawal of nivolumab.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>The following side effects have been
reported in clinical trials with nivolumab:</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><b><span lang=EN-GB>Very
common (may affect more than&nbsp;1&nbsp;in&nbsp;10&nbsp;people)</span></b></p>

<p class=EMEABodyTextIndent style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Decreased appetite</span></p>

<p class=EMEABodyTextIndent style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Nausea</span></p>

<p class=EMEABodyTextIndent style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Feeling tired or weak</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><b><span lang=EN-GB>Common
(may affect up to&nbsp;1&nbsp;in&nbsp;10&nbsp;people)</span></b></p>

<p class=EMEABodyTextIndent style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Underactive thyroid gland which can cause
tiredness or weight gain</span></p>

<p class=EMEABodyTextIndent style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Inflammation of the nerves causing numbness,
weakness, tingling or burning pain of the arms and legs, headache, dizziness</span></p>

<p class=EMEABodyTextIndent style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Inflammation of the lungs (pneumonitis),
characterised by coughing and difficulty breathing, shortness of breath
(dyspnoea), cough</span></p>

<p class=EMEABodyTextIndent style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Diarrhoea (watery, loose or soft stools), mouth
ulcers and cold sores (stomatitis), vomiting, stomach pain, constipation, dry
mouth</span></p>

<p class=EMEABodyTextIndent style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Skin rash, itching</span></p>

<p class=EMEABodyTextIndent style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Wingdings;letter-spacing:.15pt'>&sect;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-GB style='letter-spacing:.15pt'>Pain in the muscles, bones and joints</span></p>

<p class=EMEABodyTextIndent style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='letter-spacing:.15pt'>Fever, oedema
(swelling)</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><b><span lang=EN-GB>Uncommon
(may affect up to&nbsp;1&nbsp;in&nbsp;100&nbsp;people)</span></b></p>

<p class=EMEABodyTextIndent style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Bronchitis, infections of the upper respiratory
tract</span></p>

<p class=EMEABodyTextIndent style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>A disease causing the inflammation or
enlargement of a lymph node (Kikuchi lymphadenitis)</span></p>

<p class=EMEABodyTextIndent style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Allergic reaction, reactions related to the
administration of the medicine </span></p>

<p class=EMEABodyTextIndent style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Adrenal glands not working properly,
inflammation of the thyroid gland</span></p>

<p class=EMEABodyTextIndent style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>A condition in which the muscles become weak and
tire easily (myasthenic syndrome), damage to the nerves in different parts of
the body that can cause decreased feeling or affect movement</span></p>

<p class=EMEABodyTextIndent style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Fast heart rate</span></p>

<p class=EMEABodyTextIndent style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Inflammation of blood vessels</span></p>

<p class=EMEABodyTextIndent style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Fluid in the lungs</span></p>

<p class=EMEABodyTextIndent style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Inflammation of the intestines (colitis), ulcer
of the small intestines</span></p>

<p class=EMEABodyTextIndent style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Hives (itchy, bumpy rash)</span></p>

<p class=EMEABodyTextIndent style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Inflammation of muscles causing pain or
stiffness</span></p>

<p class=EMEABodyTextIndent style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Kidney disease, kidney failure.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><b><span lang=EN-GB>Tell your doctor immediately</span></b><span
lang=EN-GB> if you get any of the side effects listed above. Do not try to
treat your symptoms with other medicines on your own.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='font-family:TimesNewRoman'>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><b><span lang=EN-GB>Changes
in test results</span></b></p>

<p class=EMEABodyText><span lang=EN-GB>Nivolumab&nbsp;BMS</span><span
lang=EN-GB> may cause changes in the results of tests carried out by your
doctor. These include:</span></p>

<p class=EMEABodyTextIndent style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>A decreased number of red blood cells (which
carry oxygen), white blood cells (which are important in fighting infection) or
platelets (cells which help the blood to clot)</span></p>

<p class=EMEABodyTextIndent style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Abnormal liver function tests (increased amounts
of the liver enzymes aspartate aminotransferase, alanine aminotransferase or
alkaline phosphatase in your blood, higher blood levels of bilirubin)</span></p>

<p class=EMEABodyTextIndent style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Abnormal kidney function tests (increased
amounts of creatinine in your blood)</span></p>

<p class=EMEABodyTextIndent style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Abnormal levels of calcium, potassium,
magnesium, or sodium in your blood</span></p>

<p class=EMEABodyTextIndent style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>An increased level of the enzyme that breaks
down lipids and of the enzyme that breaks down starch.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><b><span lang=EN-GB>Reporting
of side effects</span></b></p>

<p class=EMEABodyText><span lang=EN-GB>If you get any side effects, <b>talk to
your doctor</b>.</span><span lang=EN-GB> This includes any possible side
effects not listed in this leaflet. You can also report side effects directly
via <span style='background:silver'>the national reporting system listed in </span></span><span
lang=EN-GB><a
href="http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc"><span
style='background:silver'>Appendix V</span></a>. By reporting side effects you
can help provide more information on the safety of this medicine.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading2><span lang=EN-GB>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; How
to store Nivolumab&nbsp;BMS</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Keep this medicine out of the sight and
reach of children.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Do not use this medicine after the
expiry date which is stated on the carton and the vial label </span><span
lang=EN-GB>after EXP. The expiry date refers to the last day of that month.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Store in a refrigerator
(2&deg;C&nbsp;to&nbsp;8&deg;C).</span></p>

<p class=EMEABodyText><span lang=EN-GB>Do not freeze.</span></p>

<p class=EMEABodyText><span lang=EN-GB>Store in the original package in order
to protect from light.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Do not store any unused portion of the
infusion solution for reuse. Any unused medicine or waste material should be
disposed of in accordance with local requirements.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading3><span lang=EN-GB>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Contents
of the pack and other information</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><b><span lang=EN-GB>What
Nivolumab&nbsp;BMS contains</span></b></p>

<p class=EMEABodyTextIndent style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>The active substance is nivolumab.</span></p>

<p class=EMEABodyText style='margin-left:28.35pt'><span lang=EN-GB>Each mL of
concentrate for solution for infusion contains&nbsp;10&nbsp;mg of nivolumab.</span></p>

<p class=EMEABodyText style='margin-left:28.35pt'><span lang=EN-GB>Each vial
contains either&nbsp;40&nbsp;mg (in&nbsp;4&nbsp;mL) or&nbsp;100&nbsp;mg
(in&nbsp;10&nbsp;mL) of nivolumab.</span></p>

<p class=EMEABodyText style='margin-left:28.35pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyTextIndent style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>The other ingredients are sodium citrate
dihydrate, sodium chloride (see section&nbsp;2&nbsp;&quot;</span><span
lang=EN-GB> Nivolumab&nbsp;BMS</span><span lang=EN-GB> contains sodium&quot;),
mannitol&nbsp;(E421), pentetic acid, polysorbate&nbsp;80, sodium hydroxide,
hydrochloric acid and water for injections.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><b><span lang=EN-GB>What
Nivolumab&nbsp;BMS looks like and contents of the pack</span></b></p>

<p class=EMEABodyText><span lang=EN-GB>Nivolumab&nbsp;BMS concentrate for
solution for infusion (sterile concentrate) is a clear to opalescent,
colourless to pale yellow liquid that may contain few light particles.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>It is available in packs containing
either&nbsp;1&nbsp;vial of&nbsp;4&nbsp;mL or&nbsp;1&nbsp;vial of&nbsp;10&nbsp;mL.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Not all pack sizes may be marketed.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><b><span lang=EN-GB>Marketing
Authorisation Holder</span></b></p>

<p class=EMEAAddress><span lang=EN-GB>Bristol&#8209;Myers Squibb Pharma EEIG</span></p>

<p class=EMEAAddress><span lang=EN-GB>Uxbridge Business Park</span></p>

<p class=EMEAAddress><span lang=EN-GB>Sanderson Road</span></p>

<p class=EMEAAddress><span lang=EN-GB>Uxbridge UB8&nbsp;1DH</span></p>

<p class=EMEAAddress><span lang=EN-GB>United Kingdom</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><b><span lang=EN-GB>Manufacturer</span></b></p>

<p class=EMEAAddress><span lang=EN-GB>Bristol&#8209;Myers Squibb S.r.l.</span></p>

<p class=EMEAAddress><span lang=ES>Loc. Fontana del Ceraso</span></p>

<p class=EMEAAddress><span lang=ES>03012&nbsp;Anagni (FR)</span></p>

<p class=EMEAAddress><span lang=EN-GB>Italy</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>For </span><span
lang=EN-GB>any</span><span lang=EN-GB> information about this medicine, please
contact the local representative of the Marketing Authorisation Holder.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=605
 style='margin-left:.4pt;border-collapse:collapse'>
 <tr style='page-break-inside:avoid;height:45.2pt'>
  <td width=302 valign=top style='width:3.15in;padding:0in 0in 0in 0in;
  height:45.2pt'>
  <p class=EMEATableLeft style='page-break-after:auto'><b><span lang=EN-GB>Belgique/Belgi&euml;/Belgien</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>N.V. Bristol&#8209;Myers Squibb Belgium
  S.A.</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=EN-GB>T&eacute;l/Tel:
  + 32 2 352 76 11</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=302 valign=top style='width:3.15in;padding:0in 0in 0in 0in;
  height:45.2pt'>
  <p class=EMEATableLeft style='page-break-after:auto'><b><span lang=EN-GB>Lietuva</span></b></p>
  <p class=EMEABodyText><span lang=EN-GB>Bristol&#8209;Myers Squibb
  Gy&oacute;gyszerkereskedelmi Kft.</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=EN-GB>Tel: +
  370 5 2790 762</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:44.6pt'>
  <td width=302 valign=top style='width:3.15in;padding:0in 0in 0in 0in;
  height:44.6pt'>
  <p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB>&#1041;&#1098;&#1083;&#1075;&#1072;&#1088;&#1080;&#1103;</span></b></p>
  <p class=EMEABodyText><span lang=EN-GB>Bristol&#8209;Myers Squibb
  Gy&oacute;gyszerkereskedelmi Kft.</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=EN-GB>Te&#1083;.:
  + 359 800 12 400</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='font-family:TimesNewRoman'>&nbsp;</span></p>
  </td>
  <td width=302 valign=top style='width:3.15in;padding:0in 0in 0in 0in;
  height:44.6pt'>
  <p class=EMEATableLeft style='page-break-after:auto'><b><span lang=EN-GB>Luxembourg/Luxemburg</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>N.V. Bristol&#8209;Myers Squibb Belgium
  S.A.</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=EN-GB>T&eacute;l/Tel:
  + 32 2 352 76 11</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:45.2pt'>
  <td width=302 valign=top style='width:3.15in;padding:0in 0in 0in 0in;
  height:45.2pt'>
  <p class=EMEATableLeft style='page-break-after:auto'><b><span lang=EN-GB>&#268;esk&aacute;
  republika</span></b></p>
  <p class=EMEABodyText><span lang=EN-GB>Bristol&#8209;Myers Squibb spol. s
  r.o.</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=EN-GB>Tel: +
  420 221 016 111</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=302 valign=top style='width:3.15in;padding:0in 0in 0in 0in;
  height:45.2pt'>
  <p class=EMEATableLeft style='page-break-after:auto'><b><span lang=EN-GB>Magyarorsz&aacute;g</span></b></p>
  <p class=EMEABodyText><span lang=EN-GB>Bristol&#8209;Myers Squibb
  Gy&oacute;gyszerkereskedelmi Kft.</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=EN-GB>Tel.: +
  36 1 301 9700</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:45.2pt'>
  <td width=302 valign=top style='width:3.15in;padding:0in 0in 0in 0in;
  height:45.2pt'>
  <p class=EMEATableLeft style='page-break-after:auto'><b><span lang=EN-GB>Danmark</span></b></p>
  <p class=EMEABodyText><span lang=EN-GB>Bristol&#8209;Myers Squibb</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=EN-GB>Tlf: +
  45 45 93 05 06</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=302 valign=top style='width:3.15in;padding:0in 0in 0in 0in;
  height:45.2pt'>
  <p class=EMEATableLeft style='page-break-after:auto'><b><span lang=EN-GB>Malta</span></b></p>
  <p class=EMEABodyText><span lang=EN-GB style='font-variant:small-caps'>Bristol&#8209;Myers
  Squibb S.r.l.</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=EN-GB>Tel: +
  39 06 50 39 61</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:44.6pt'>
  <td width=302 valign=top style='width:3.15in;padding:0in 0in 0in 0in;
  height:44.6pt'>
  <p class=EMEATableLeft style='page-break-after:auto'><b><span lang=EN-GB>Deutschland</span></b></p>
  <p class=EMEABodyText><span lang=EN-GB>Bristol&#8209;Myers Squibb GmbH &amp;
  Co. KGaA</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=EN-GB>Tel: +
  49 89 121 42&#8209;0</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=302 valign=top style='width:3.15in;padding:0in 0in 0in 0in;
  height:44.6pt'>
  <p class=EMEATableLeft style='page-break-after:auto'><b><span lang=EN-GB>Nederland</span></b></p>
  <p class=EMEABodyText><span lang=EN-GB>Bristol&#8209;Myers Squibb B.V.</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=EN-GB>Tel: +
  31 (0)30 300 2222</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:44.0pt'>
  <td width=302 valign=top style='width:3.15in;padding:0in 0in 0in 0in;
  height:44.0pt'>
  <p class=EMEATableLeft style='page-break-after:auto'><b><span lang=EN-GB>Eesti</span></b></p>
  <p class=EMEABodyText><span lang=EN-GB>Bristol&#8209;Myers Squibb
  Gy&oacute;gyszerkereskedelmi Kft.</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=EN-GB>Tel: </span><span
  lang=EN-GB>+ 372 6827 400</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=302 valign=top style='width:3.15in;padding:0in 0in 0in 0in;
  height:44.0pt'>
  <p class=EMEATableLeft style='page-break-after:auto'><b><span lang=EN-GB>Norge</span></b></p>
  <p class=EMEABodyText><span lang=EN-GB>Bristol&#8209;Myers Squibb Norway Ltd</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=EN-GB>Tlf: +
  47 67 55 53 50</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:47.6pt'>
  <td width=302 valign=top style='width:3.15in;padding:0in 0in 0in 0in;
  height:47.6pt'>
  <p class=EMEATableLeft style='page-break-after:auto'><b><span lang=EN-GB>&#917;&#955;&#955;&#940;&#948;&#945;</span></b></p>
  <p class=EMEABodyText><span lang=EN-GB style='font-variant:small-caps'>Bristol&#8209;Myers
  Squibb A.E.</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=EN-GB>&#932;&#951;&#955;:
  + 30 210 6074300</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=302 valign=top style='width:3.15in;padding:0in 0in 0in 0in;
  height:47.6pt'>
  <p class=EMEATableLeft style='page-break-after:auto'><b><span lang=EN-GB>&Ouml;sterreich</span></b></p>
  <p class=EMEABodyText><span lang=EN-GB>Bristol&#8209;Myers Squibb GesmbH</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=EN-GB>Tel: +
  43 1 60 14 30</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:55.55pt'>
  <td width=302 valign=top style='width:3.15in;padding:0in 0in 0in 0in;
  height:55.55pt'>
  <p class=EMEATableLeft style='page-break-after:auto'><b><span lang=EN-GB>Espa&ntilde;a</span></b></p>
  <p class=EMEABodyText><span lang=EN-GB style='font-variant:small-caps'>Bristol&#8209;Myers
  Squibb, S.A.</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=EN-GB>Tel: +
  34 91 456 53 00</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=302 valign=top style='width:3.15in;padding:0in 0in 0in 0in;
  height:55.55pt'>
  <p class=EMEATableLeft style='page-break-after:auto'><b><span lang=EN-GB>Polska</span></b></p>
  <p class=EMEABodyText><span lang=EN-GB style='font-variant:small-caps'>Bristol&#8209;Myers
  Squibb Polska Sp. z o.o.</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=EN-GB>Tel.: +
  48 22 5796666</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:44.6pt'>
  <td width=302 valign=top style='width:3.15in;padding:0in 0in 0in 0in;
  height:44.6pt'>
  <p class=EMEATableLeft style='page-break-after:auto'><b><span lang=EN-GB>France</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>Bristol&#8209;Myers Squibb SARL</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=EN-GB>T&eacute;l:
  + 33 (0)810 410 500</span></p>
  <p class=EMEABodyText><span lang=EN-GB style='font-variant:small-caps'>&nbsp;</span></p>
  </td>
  <td width=302 valign=top style='width:3.15in;padding:0in 0in 0in 0in;
  height:44.6pt'>
  <p class=EMEATableLeft style='page-break-after:auto'><b><span lang=ES>Portugal</span></b></p>
  <p class=EMEABodyText><span lang=ES>Bristol&#8209;Myers Squibb
  Farmac&ecirc;utica Portuguesa, S.A.</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=EN-GB>Tel: +
  351 21 440 70 00</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:44.6pt'>
  <td width=302 valign=top style='width:3.15in;padding:0in 0in 0in 0in;
  height:44.6pt'>
  <p class=EMEATableLeft style='page-break-after:auto'><b><span lang=EN-GB>Hrvatska</span></b></p>
  <p class=EMEABodyText><span lang=EN-GB>Bristol&#8209;Myers Squibb spol. s
  r.o.</span></p>
  <p class=EMEABodyText><span lang=EN-GB style='font-variant:small-caps'>Tel:
  +385 (1) 6311&#8209;833</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
  <td width=302 valign=top style='width:3.15in;padding:0in 0in 0in 0in;
  height:44.6pt'>
  <p class=EMEATableLeft style='page-break-after:auto'><b><span lang=EN-GB>Rom&acirc;nia</span></b></p>
  <p class=EMEABodyText><span lang=EN-GB>Bristol&#8209;Myers Squibb
  Gy&oacute;gyszerkereskedelmi Kft.</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=EN-GB>Tel: +
  40 (0)21 272 16 00</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:44.6pt'>
  <td width=302 valign=top style='width:3.15in;padding:0in 0in 0in 0in;
  height:44.6pt'>
  <p class=EMEATableLeft style='page-break-after:auto'><b><span lang=EN-GB>Ireland</span></b></p>
  <p class=EMEABodyText><span lang=EN-GB>Bristol&#8209;Myers Squibb
  Pharmaceuticals Ltd</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=EN-GB>Tel: +
  353 (1 800) 749 749</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=302 valign=top style='width:3.15in;padding:0in 0in 0in 0in;
  height:44.6pt'>
  <p class=EMEATableLeft style='page-break-after:auto'><b><span lang=EN-GB>Slovenija</span></b></p>
  <p class=EMEABodyText><span lang=EN-GB>Bristol&#8209;Myers Squibb spol. s
  r.o.</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=EN-GB>Tel: +
  386 1 236 47 00</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:45.2pt'>
  <td width=302 valign=top style='width:3.15in;padding:0in 0in 0in 0in;
  height:45.2pt'>
  <p class=EMEATableLeft style='page-break-after:auto'><b><span lang=EN-GB>&Iacute;sland</span></b></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=EN-GB>Vistor
  hf.</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=EN-GB>S&iacute;mi</span><span
  lang=EN-GB>: + 354 535 7000</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=302 valign=top style='width:3.15in;padding:0in 0in 0in 0in;
  height:45.2pt'>
  <p class=EMEATableLeft style='page-break-after:auto'><b><span lang=EN-GB>Slovensk&aacute;
  republika</span></b></p>
  <p class=EMEABodyText><span lang=EN-GB>Bristol&#8209;Myers Squibb spol. s
  r.o.</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=EN-GB>Tel: +
  421 2 59298411</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:44.6pt'>
  <td width=302 valign=top style='width:3.15in;padding:0in 0in 0in 0in;
  height:44.6pt'>
  <p class=EMEATableLeft style='page-break-after:auto'><b><span lang=EN-GB>Italia</span></b></p>
  <p class=EMEABodyText><span lang=EN-GB style='font-variant:small-caps'>Bristol&#8209;Myers
  Squibb S.r.l.</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=EN-GB>Tel: +
  39 06 50 39 61</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=302 valign=top style='width:3.15in;padding:0in 0in 0in 0in;
  height:44.6pt'>
  <p class=EMEATableLeft style='page-break-after:auto'><b><span lang=EN-GB>Suomi/Finland</span></b></p>
  <p class=EMEABodyText><span lang=EN-GB>Oy Bristol&#8209;Myers Squibb
  (Finland) Ab</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=EN-GB>Puh/Tel:
  + 358 9 251 21 230</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:38.6pt'>
  <td width=302 valign=top style='width:3.15in;padding:0in 0in 0in 0in;
  height:38.6pt'>
  <p class=EMEATableLeft style='page-break-after:auto'><b><span lang=EN-GB>&#922;&#973;&#960;&#961;&#959;&#962;</span></b></p>
  <p class=EMEABodyText><span lang=EN-GB style='font-variant:small-caps'>Bristol&#8209;Myers
  Squibb A.E.</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=EN-GB>&#932;&#951;&#955;:
  + 357 800 92666</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=302 valign=top style='width:3.15in;padding:0in 0in 0in 0in;
  height:38.6pt'>
  <p class=EMEATableLeft style='page-break-after:auto'><b><span lang=EN-GB>Sverige</span></b></p>
  <p class=EMEABodyText><span lang=EN-GB>Bristol&#8209;Myers Squibb AB</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=EN-GB>Tel: +
  46 8 704 71 00</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:60.95pt'>
  <td width=302 valign=top style='width:3.15in;padding:0in 0in 0in 0in;
  height:60.95pt'>
  <p class=EMEATableLeft style='page-break-after:auto'><b><span lang=EN-GB>Latvija</span></b></p>
  <p class=EMEABodyText><span lang=EN-GB>Bristol&#8209;Myers Squibb
  Gy&oacute;gyszerkereskedelmi Kft.</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=EN-GB>Tel: +
  371 67 50 21 85</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=302 valign=top style='width:3.15in;padding:0in 0in 0in 0in;
  height:60.95pt'>
  <p class=EMEATableLeft style='page-break-after:auto'><b><span lang=EN-GB>United
  Kingdom</span></b></p>
  <p class=EMEABodyText><span lang=EN-GB>Bristol&#8209;Myers Squibb
  Pharmaceuticals Ltd</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=EN-GB>Tel: +
  44 (0800) 731 1736</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
</table>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><b><span lang=EN-GB>This leaflet was last revised in</span></b></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Detailed information on this medicine is
available on the European Medicines Agency web site: <a
href="http://www.ema.europa.eu">http://www.ema.europa.eu</a></span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>-------------------------------------------------------------------------------------------------------------------------</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><b><span lang=EN-GB>The
following information is intended for healthcare professionals only:</span></b></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><b><u><span lang=EN-GB>Preparation
and administration of </span><span lang=EN-GB>Nivolumab&nbsp;BMS</span></u></b></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Preparation should be performed by
trained personnel in accordance with good practices rules, especially with
respect to asepsis.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><b><span lang=EN-GB>Calculating
the dose</span></b></p>

<p class=EMEABodyText><span lang=EN-GB>The <b>prescribed dose</b> for the
patient is given in mg/kg. Based on this prescribed dose, calculate the total
dose to be given. More than one vial of Nivolumab&nbsp;BMS concentrate may be
needed to give the total dose for the patient.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyTextIndent style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>The <b>total nivolumab dose</b> in
mg&nbsp;=&nbsp;the patient&#8217;s weight in kg&nbsp;&times;&nbsp;the
prescribed dose in mg/kg. </span></p>

<p class=EMEABodyTextIndent style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>The <b>volume of Nivolumab&nbsp;BMS concentrate</b>
to prepare the dose (mL)&nbsp;=&nbsp;the total dose in mg, divided by&nbsp;10
(the Nivolumab&nbsp;BMS concentrate strength is&nbsp;10&nbsp;mg/mL). </span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><b><span lang=EN-GB>Preparing
the infusion</span></b></p>

<p class=EMEABodyText><b><span lang=EN-GB>Take care to ensure aseptic handling</span></b><span
lang=EN-GB> when you prepare the infusion. The infusion should be prepared in a
laminar flow hood or safety cabinet using standard precautions for the safe
handling of intravenous agents.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Nivolumab&nbsp;BMS</span><span
lang=EN-GB> can be used for intravenous administration either:</span></p>

<p class=EMEABodyTextIndent style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB>without dilution,</span></b><span lang=EN-GB>
after transfer to an infusion container using an appropriate sterile syringe;</span></p>

<p class=EMEABodyText style='margin-left:28.35pt'><span lang=EN-GB>or</span></p>

<p class=EMEABodyTextIndent style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB>after diluting</span></b><span lang=EN-GB> to
concentrations as low as&nbsp;1&nbsp;mg/mL. The final infusion concentration
should range between&nbsp;1&nbsp;and&nbsp;10&nbsp;mg/mL. Nivolumab&nbsp;BMS
concentrate may be diluted with either: </span></p>

<p class=EMEABodyTextIndent style='margin-left:85.05pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>sodium chloride&nbsp;9&nbsp;mg/mL&nbsp;(0.9%)
solution for injection; or</span></p>

<p class=EMEABodyTextIndent style='margin-left:85.05pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>50&nbsp;mg/mL&nbsp;(5%) glucose solution for
injection. </span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><b><span lang=EN-GB>STEP 1</span></b></p>

<p class=EMEABodyTextIndent style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Inspect the Nivolumab&nbsp;BMS concentrate for
particulate matter or discoloration. Do not shake the vial. Nivolumab&nbsp;BMS
concentrate is a clear to opalescent, colourless to pale yellow liquid that may
contain few light particles. </span></p>

<p class=EMEABodyTextIndent style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Withdraw the required volume of Nivolumab&nbsp;BMS
concentrate using an appropriate sterile syringe. </span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><b><span lang=EN-GB>STEP 2</span></b></p>

<p class=EMEABodyTextIndent style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Transfer the concentrate into a sterile,
evacuated glass bottle or intravenous container (PVC or polyolefin). </span></p>

<p class=EMEABodyTextIndent style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Wingdings'>&sect;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>If applicable, dilute with the required volume
of sodium chloride&nbsp;9&nbsp;mg/mL&nbsp;(0.9%) solution for injection
or&nbsp;50&nbsp;mg/mL&nbsp;(5%) glucose solution for injection. Gently mix the
infusion by manual rotation. Do not shake.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><b><span lang=EN-GB>Administration</span></b></p>

<p class=EMEABodyText><span lang=EN-GB>Nivolumab&nbsp;BMS</span><span
lang=EN-GB> infusion must not be administered as an intravenous push or bolus
injection.</span></p>

<p class=EMEABodyText><span lang=EN-GB>Administer the Nivolumab&nbsp;BMS
infusion <b>intravenously over a period of 60&nbsp;minutes</b>.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Nivolumab&nbsp;BMS</span><span
lang=EN-GB> infusion should not be infused at the same time in the same
intravenous line with other agents. Use a separate infusion line for the
infusion.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Use an infusion set and an in&#8209;line,
sterile, non&#8209;pyrogenic, low protein binding filter (pore size
of&nbsp;0.2&nbsp;&#956;m&nbsp;to&nbsp;1.2&nbsp;&#956;m).</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Nivolumab&nbsp;BMS</span><span
lang=EN-GB> infusion is compatible with:</span></p>

<p class=EMEABodyTextIndent><span lang=EN-GB style='font-family:Wingdings'>&sect;<span
style='font:7.0pt "Times New Roman"'>&nbsp; </span></span><span lang=EN-GB>PVC
containers</span></p>

<p class=EMEABodyTextIndent><span lang=EN-GB style='font-family:Wingdings'>&sect;<span
style='font:7.0pt "Times New Roman"'>&nbsp; </span></span><span lang=EN-GB>Polyolefin
containers</span></p>

<p class=EMEABodyTextIndent><span lang=EN-GB style='font-family:Wingdings'>&sect;<span
style='font:7.0pt "Times New Roman"'>&nbsp; </span></span><span lang=EN-GB>Glass
bottles</span></p>

<p class=EMEABodyTextIndent><span lang=EN-GB style='font-family:Wingdings'>&sect;<span
style='font:7.0pt "Times New Roman"'>&nbsp; </span></span><span lang=EN-GB>PVC
infusion sets</span></p>

<p class=EMEABodyTextIndent><span lang=EN-GB style='font-family:Wingdings'>&sect;<span
style='font:7.0pt "Times New Roman"'>&nbsp; </span></span><span lang=EN-GB>In&#8209;line
filters with polyethersulfone membranes with pore sizes
of&nbsp;0.2&nbsp;&micro;m to&nbsp;1.2&nbsp;&micro;m.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>After administration of the nivolumab
dose, flush the line with sodium chloride&nbsp;9&nbsp;mg/mL&nbsp;(0.9%)
solution for injection or&nbsp;50&nbsp;mg/mL&nbsp;(5%) glucose solution for
injection.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><b><span lang=EN-GB>Storage
conditions and shelf life</span></b></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB>Unopened
vial</span></u></p>

<p class=EMEABodyText><span lang=EN-GB>Nivolumab&nbsp;BMS</span><span
lang=EN-GB> must be <b>stored in a refrigerator</b>
(2&deg;C&nbsp;to&nbsp;8&deg;C). The vials must be kept in the original package
in order to protect from light. Nivolumab&nbsp;BMS should not be frozen.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Do not use Nivolumab&nbsp;BMS after the
expiry date which is stated on the carton and on the vial label after EXP. The
expiry date refers to the last day of that month.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB>Nivolumab&nbsp;BMS
infusion</span></u></p>

<p class=EMEABodyText><span lang=EN-GB>Nivolumab&nbsp;BMS</span><span
lang=EN-GB> infusion must be completed within&nbsp;24&nbsp;hours of
preparation. If not used immediately, the solution may be stored under
refrigeration conditions (2&deg;C&#8209;8&deg;C) and protected from light for
up to&nbsp;24&nbsp;hours [a maximum of&nbsp;4&nbsp;hours of the
total&nbsp;24&nbsp;hours can be at room temperature (20&deg;C&#8209;25&deg;C)
and room light]. Other in&#8209;use storage time and conditions are the
responsibility of the user.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><b><span lang=EN-GB>Disposal</span></b></p>

<p class=EMEABodyText><span lang=EN-GB>Do not store any unused portion of the
infusion solution for reuse. Any unused medicine or waste material should be
disposed of in accordance with local requirements.</span></p>

</div>

</body>

</html>
